Third RARE
, O
consistent O
with O
these O
data O
, O
N O
- O
acetylcysteine RARE
reduced O
the O
stimulatory O
effect O
of O
HGF I-GENE
on O
stress O
kinase I-GENE
activities O
, O
while O
p42 NUMERIC
/ O
44 NUMERIC
mitogen I-GENE
activated I-GENE
kinase I-GENE
( O
MAPK I-GENE
) I-GENE
was O
unmodified RARE
, O
suggesting O
an O
involvement O
of O
c I-GENE
- I-GENE
Jun I-GENE
- I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) I-GENE
and O
p38 I-GENE
MAPK I-GENE
in O
HIF I-GENE
- I-GENE
1 I-GENE
activation O
. O

The O
Sox RARE
gene I-GENE
family I-GENE
( O
Sry RARE
like O
HMG I-GENE
box I-GENE
gene I-GENE
) O
is O
characterised RARE
by O
a O
conserved O
DNA O
sequence O
encoding O
a O
domain O
of O
approximately O
80 O
amino O
acids O
which O
is O
responsible O
for O
sequence O
specific O
DNA O
binding O
. O

Respiratory RARE
parameters O
suggested O
that O
M6G NUMERIC
produced O
less O
respiratory O
depression O
than O
morphine O
. O

This O
slow O
progression O
through O
the O
early O
G1 O
- O
phase O
resulted O
in O
decreased O
phosphorylation O
of O
the O
RB I-GENE
protein I-GENE
and O
subsequent O
delay O
into O
the O
S O
phase O
transition O
. O

Responses RARE
of O
TLD ALLCAPS
Mg2SiO4 NUMERIC
: O
Tb RARE
and O
radiophotoluminescent RARE
glass O
to O
heavy O
charged O
particles O
and O
space O
radiation O
. O

In O
the O
meantime RARE
, O
one O
has O
succeeded RARE
to O
establish O
the O
deammonification RARE
processes O
in O
a O
continuous O
flow O
moving RARE
- O
bed RARE
pilot RARE
plant O
. O

An O
18 O
- O
kb O
genomic O
clone O
including O
sequences O
encoding O
for O
the O
two O
GHS ALLCAPS
- O
R O
variants O
was O
isolated O
. O

In O
the O
further O
development O
of O
bladder O
neck O
suspension RARE
according O
to O
Stamey RARE
- O
Pereyra RARE
, O
the O
use O
of O
miniature RARE
bone O
anchors RARE
received O
considerable O
support O
. O

CHAP ALLCAPS
and O
the O
Department RARE
of O
Veterans RARE
Affairs RARE
. O

Finally O
, O
a O
chromogenic RARE
method O
was O
used O
, O
based O
on O
thrombin I-GENE
inhibition O
and O
the O
substrate O
S O
- O
2238 NUMERIC
. O

As O
an O
oral O
, O
nontoxic RARE
compound O
with O
a O
mechanism O
of O
action O
distinct O
from O
that O
of O
ABL I-GENE
tyrosine I-GENE
kinase I-GENE
inhibition O
, O
FTI ALLCAPS
SCH66336 NUMERIC
shows O
promise RARE
for O
the O
treatment O
of O
BCR I-GENE
/ I-GENE
ABL I-GENE
- I-GENE
induced O
leukemia O
. O

Recruitment RARE
of O
an O
RNA O
polymerase O
II O
complex O
is O
mediated O
by O
the O
constitutive O
activation O
domain O
in O
CREB I-GENE
, O
independently O
of O
CREB I-GENE
phosphorylation O
. O

Our O
results O
are O
reassuring RARE
and O
we O
therefore O
advise RARE
that O
in O
patients O
undergoing O
free O
jejunum RARE
flap O
reconstruction O
of O
the O
hypopharyngo RARE
- O
esophageal O
tract O
voice RARE
restoration RARE
should O
be O
attempted RARE
by O
placing RARE
a O
voice RARE
prosthesis RARE
through O
a O
secondary O
tracheo RARE
- O
esophageal O
puncture RARE
and O
providing O
intensive O
speech O
training O
. O

Regarding RARE
gestational O
risk O
, O
3 O
, O
243 NUMERIC
drugs O
used O
( O
34 O
%) O
belonged RARE
to O
category O
A O
risk O
, O
1 O
, O
923 NUMERIC
( O
22 O
. O
6 O
%) O
to O
category O
B O
, O
3 O
, O
798 NUMERIC
( O
39 O
. O
7 O
%) O
to O
category O
C O
, O
289 NUMERIC
( O
3 O
. O
0 O
%) O
to O
category O
D O
, O
and O
55 O
( O
0 O
. O
6 O
%) O
to O
category O
X O
. O

The O
human O
ABCG1 NUMERIC
gene I-GENE
encodes O
a O
member O
of O
the O
ATP O
- O
binding O
cassette O
( O
ABC ALLCAPS
) O
superfamily I-GENE
of O
transporter I-GENE
proteins I-GENE
and O
is O
highly O
induced O
when O
macrophages O
are O
incubated O
with O
oxysterols RARE
. O

At O
the O
end O
of O
each O
day O
of O
migration O
the O
pulmonary O
hemolymph RARE
PO2 O
decreased O
by O
1 O
- O
2 O
. O
5 O
kPa RARE
, O
but O
the O
hemocyanin RARE
remained O
saturated RARE
with O
O2 O
and O
the O
venous O
reserve O
was O
largely O
unchanged O
( O
O2 O
> O
0 O
. O
4 O
mmol O
x O
l O
(- O
1 O
)). RARE

We O
have O
investigated O
the O
role O
of O
NGF ALLCAPS
in O
regulating O
gene O
transcription O
in O
PC12 O
and O
INS ALLCAPS
- O
1 O
cells O
, O
in O
order O
to O
define O
if O
there O
are O
NGF ALLCAPS
- O
regulated O
genes O
per O
se RARE
. O

Thus O
, O
through O
a O
change O
in O
conformation O
upon O
repair O
of O
the O
6RG NUMERIC
lesion O
, O
MGMT ALLCAPS
switches RARE
from O
a O
DNA O
repair O
factor O
to O
a O
transcription O
regulator O
( O
R O
- O
MGMT ALLCAPS
), O
enabling RARE
the O
cell O
to O
sense O
as O
well O
as O
respond O
to O
mutagens RARE
. O

TaqMan RARE
analysis O
of O
gene O
expression O
following O
chronic O
FA ALLCAPS
treatment O
showed O
neither O
a O
decrease O
in O
the O
amount O
of O
leptin I-GENE
receptor I-GENE
( O
Ob RARE
- O
R O
) O
mRNA O
, O
nor O
an O
increase O
in O
the O
negative O
regulators O
of O
STAT I-GENE
signalling O
, O
SOCS3 NUMERIC
( O
suppressors O
of O
cytokine O
signalling O
) O
or O
cytokine O
inducible O
sequence O
( O
CIS ALLCAPS
). O

Nine RARE
animals O
served RARE
as O
control O
animals O
, O
whereas O
20 O
animals O
received O
a O
focal O
arachnoid RARE
scar RARE
at O
C1 O
- O
C2 O
, O
which O
was O
produced O
by O
placement O
of O
a O
kaolin RARE
- O
soaked RARE
fibrin I-GENE
sponge RARE
on O
the O
posterior O
surface O
of O
the O
spinal O
cord O
. O

A O
comparison O
of O
the O
duplicated O
Vkappa RARE
genes O
suggests O
positive O
selection O
on O
the O
complementarity O
- O
determining O
regions O
of O
the O
duplicated O
genes O
by O
point O
mutations O
. O

They O
have O
not O
been O
previously O
reported O
as O
a O
reaction O
to O
i O
. O
v O
. O
contrast O
material O
. O

The O
presence O
of O
AS ALLCAPS
- O
oligo RARE
had O
no O
further O
effect O
on O
the O
FSH I-GENE
- I-GENE
mediated O
activation O
of O
the O
EB ALLCAPS
*- RARE
mTf RARE
- O
CAT I-GENE
construct I-GENE
but O
reduced O
cAMP O
- O
mediated O
activation O
. O

The O
homologous O
active O
- O
site O
framework RARE
of O
these O
enzymes O
with O
distinct O
structures O
suggests O
convergent RARE
evolution O
of O
a O
common O
catalytic O
mechanism O
. O

Additional RARE
education O
and O
research O
is O
needed O
to O
provide O
further O
direction O
for O
intervention O
and O
incorporation O
into O
practice O
. O

Many O
of O
the O
important O
genes O
associated O
with O
G1 O
regulation O
have O
been O
shown O
to O
play O
a O
key O
role O
in O
proliferation O
, O
differentiation O
and O
oncogenic O
transformation O
and O
programmed O
cell O
death O
( O
apoptosis O
). O

Drug O
interactions O
have O
been O
found O
with O
drugs O
that O
compete O
for O
the O
same O
CYP450 NUMERIC
isoenzymes RARE
as O
statins RARE
. O

Regulation O
of O
laminin RARE
beta2 NUMERIC
chain I-GENE
gene I-GENE
expression O
in O
human O
cancer O
cell O
lines O
. O

Mutation O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
site I-GENE
in O
the O
Mdr1b NUMERIC
promoter I-GENE
prevents O
its O
induction O
by O
TNF I-GENE
- I-GENE
alpha I-GENE
. O

Effect O
of O
heat O
treatments O
on O
the O
meltability RARE
of O
cheeses RARE
. O

In O
vitro O
binding O
studies O
demonstrate O
that O
eIF I-GENE
- I-GENE
5A NUMERIC
is O
required O
for O
efficient O
interaction O
of O
Rev I-GENE
- I-GENE
NES ALLCAPS
with O
CRM1 NUMERIC
/ O
exportin1 NUMERIC
and O
that O
eIF I-GENE
- I-GENE
5A NUMERIC
interacts O
with O
the O
nucleoporins RARE
CAN ALLCAPS
/ O
nup214 NUMERIC
, O
nup153 NUMERIC
, O
nup98 NUMERIC
, O
and O
nup62 NUMERIC
. O

Forced RARE
expression O
of O
BZAP45 NUMERIC
strongly O
stimulates O
H4 I-GENE
promoter I-GENE
( O
nt O
- O
215 O
to O
- O
1 O
)/ O
CAT I-GENE
reporter I-GENE
gene I-GENE
activity O
. O

Copyright O
2001 NUMERIC
Academic O
Press O
. O

The O
diagnosis O
of O
HCV O
arthritis O
in O
patients O
with O
positive O
rheumatoid O
factor O
and O
chronic O
inflammatory O
polyarthritis RARE
may O
be O
difficult O
. O

The O
UBA ALLCAPS
domains O
of O
RAD23 NUMERIC
and O
DDI1 NUMERIC
are O
required O
for O
these O
interactions O
. O

E47 NUMERIC
protein I-GENE
levels O
remain RARE
high O
until O
the O
double O
positive O
developmental O
stage O
, O
at O
which O
point O
they O
drop O
to O
relatively O
moderate O
levels O
, O
and O
are O
further O
downregulated RARE
upon O
transition O
to O
the O
single O
positive O
stage O
. O

By O
Caveman RARE
. O

These O
findings O
suggest O
that O
the O
adapter RARE
Gab1 NUMERIC
may O
redirect RARE
c I-GENE
- I-GENE
Met I-GENE
signaling O
through O
PI3K NUMERIC
away RARE
from O
a O
c I-GENE
- I-GENE
Akt I-GENE
/ I-GENE
Pak1 NUMERIC
cell O
survival O
pathway O
. O

Another O
mutant O
, O
T255A NUMERIC
, O
lost O
the O
ability O
to O
bind O
E4orf6 NUMERIC
, O
but O
unexpectedly RARE
, O
viral O
late O
- O
gene O
expression O
was O
not O
affected O
. O

However O
, O
the O
N63S NUMERIC
mutation O
in O
the O
wild O
- O
type O
VP5 NUMERIC
background O
increased O
the O
interaction O
, O
as O
judged O
by O
the O
beta O
- O
galactosidase I-GENE
activity O
, O
by O
a O
factor O
of O
9 O
relative O
to O
when O
the O
PR7 NUMERIC
mutation O
was O
present O
. O

Here O
we O
report O
the O
isolation O
and O
characterization O
of O
the O
forkhead RARE
homologue O
in O
rhabdomyosarcoma RARE
( O
FKHR ALLCAPS
), O
a O
recently O
described O
member O
of O
the O
hepatocyte RARE
nuclear O
factor O
3 O
/ O
forkhead RARE
homeotic I-GENE
gene I-GENE
family I-GENE
, O
as O
a O
nuclear O
hormone O
receptor O
( O
NR ALLCAPS
) O
intermediary RARE
protein O
. O

Unlike O
other O
progenitor O
cells O
of O
the O
brain O
, O
SVZa RARE
progenitor O
cells O
have O
the O
capacity O
to O
divide RARE
even O
though O
they O
express O
a O
neuronal O
phenotype O
. O

We O
previously O
reported O
that O
Tax I-GENE
induced O
cell O
cycle O
progression O
from O
G0 NUMERIC
/ O
G1 O
phase O
to O
S O
and O
G2 O
/ O
M O
phases O
in O
human O
T O
- O
cell O
line O
Kit RARE
225 NUMERIC
cells O
. O

Phosphotyrosyl RARE
peptides O
block O
Stat3 I-GENE
- I-GENE
mediated O
DNA O
binding O
activity O
, O
gene O
regulation O
, O
and O
cell O
transformation O
. O

In O
Exp RARE
. O

Human O
brain O
cDNA O
library O
screening O
and O
5 O
' O
rapid O
amplification O
of O
cDNA O
ends O
yielded O
full O
- O
length O
DENTT ALLCAPS
cDNA O
containing O
an O
1899 NUMERIC
- O
bp O
open O
reading O
frame O
encoding O
a O
predicted O
633 NUMERIC
- O
amino O
- O
acid O
protein O
with O
four O
potential O
nuclear O
localization O
signals O
( O
NLSs RARE
) O
and O
two O
coiled O
- O
coil O
regions O
. O

NaeI RARE
, O
a O
novel O
DNA O
endonuclease O
, O
shows O
topoisomerase I-GENE
and O
recombinase RARE
activities O
when O
a O
Lys O
residue O
is O
substituted O
for O
Leu O
43 O
. O

We O
used O
a O
rev RARE
- O
and O
RRE ALLCAPS
- O
defective O
HIV O
type O
1 O
( O
HIV O
- O
1 O
) O
molecular O
clone O
in O
complementation O
experiments O
to O
establish O
a O
method O
for O
the O
rapid O
isolation O
of O
posttranscriptional O
regulatory O
elements O
from O
the O
mammalian O
genome O
by O
selecting RARE
for O
rescue O
of O
virus O
replication O
. O

OBJECTIVES O
: O
The O
objective O
of O
this O
review O
was O
to O
compare O
the O
effectiveness O
, O
safety O
and O
acceptability RARE
of O
the O
diaphragm O
with O
and O
without O
spermicide RARE
. O

DESIGN O
: O
Retrospective RARE
study O
. O

Considering RARE
that O
the O
reactor RARE
is O
thoroughly RARE
mixed O
during O
each O
discharge O
and O
that O
LD50 O
= O
0 O
. O
9 O
values O
are O
nearly O
independent O
of O
E O
. O
coli O
concentrations O
in O
the O
range O
of O
2 O
x O
10 O
( O
3 O
) O
< O
or O
= O
E O
coli O
/ O
cfu RARE
mL O
(- O
1 O
) O
< O
or O
= O
3 O
x O
10 O
( O
6 O
), O
we O
ascribe RARE
the O
nonexponential RARE
Pn RARE
decay O
of O
single O
- O
strain O
E O
. O
coli O
colonies O
to O
a O
shielding RARE
phenomenon O
where O
inactive O
cells O
protect O
the O
successively RARE
smaller O
numbers O
of O
viable O
cells O
in O
the O
EHD ALLCAPS
. O

These O
genes O
encode O
a O
tryptophanyl RARE
tRNA I-GENE
, O
the O
protein O
translocase RARE
component O
SecE RARE
, O
the O
antiterminator RARE
protein O
NusG RARE
, O
and O
the O
ribosomal O
proteins O
L11 NUMERIC
and O
L1 O
in O
addition O
to O
PkwR RARE
, O
a O
putative O
regulatory O
protein O
of O
the O
LacI RARE
- O
GalR RARE
family O
. O

Body RARE
fat O
distribution O
was O
determined O
by O
abdominal O
computed O
tomography O
. O

The O
telomerase I-GENE
RNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
responsible O
for O
maintenance O
of O
telomeric O
DNA O
at O
chromosome O
ends O
, O
is O
usually O
inactive O
in O
most O
primary O
somatic O
human O
cells O
, O
but O
is O
specifically O
activated O
with O
in O
vitro O
immortalization RARE
and O
during O
tumorigenesis O
. O

This O
is O
a O
challenging RARE
task O
insofar RARE
as O
direct O
measures O
of O
ISF ALLCAPS
glucose O
are O
not O
readily O
available O
. O

SELECTION ALLCAPS
CRITERIA ALLCAPS
: O
All O
randomised O
controlled O
trials O
comparing O
IUSs RARE
with O
other O
forms O
of O
reversible O
contraceptives RARE
and O
reporting RARE
on O
pre O
- O
determined O
outcomes O
in O
women O
of O
reproductive O
years O
. O

There O
was O
a O
statistically O
significant O
correlation O
between O
simultaneous O
weekly O
average O
pollen O
levels O
in O
Philadelphia RARE
and O
in O
Cherry RARE
Hill RARE
( O
Acer RARE
, O
r O
( O
p O
) O
= O
0 O
. O
987 NUMERIC
, O
Quercus RARE
, O
r O
( O
p O
) O
= O
0 O
. O
645 NUMERIC
, O
Betula RARE
, O
r O
( O
p O
) O
= O
0 O
. O
896 NUMERIC
, O
Pinus RARE
, O
r O
( O
p O
) O
= O
0 O
. O
732 NUMERIC
, O
Cupressaceae RARE
, O
r O
( O
p O
) O
= O
0 O
. O
695 NUMERIC
, O
Poaceae RARE
, O
r O
( O
p O
) O
= O
0 O
. O
950 NUMERIC
, O
Ambrosia RARE
, O
r O
( O
p O
) O
= O
0 O
. O
903 NUMERIC
, O
and O
Rumex RARE
, O
r O
( O
p O
) O
= O
0 O
. O
572 NUMERIC
, O
P O
< O
0 O
. O
001 O
). O

Through RARE
two O
novel O
mechanisms O
, O
Arf RARE
inhibits O
the O
oncoprotein RARE
Hdm2 NUMERIC
, O
a O
negative O
regulator O
of O
p53 I-GENE
. O

2 O
: O
The O
dynamic O
moduli RARE
of O
microcrystalline RARE
cellulose RARE
. O

Such O
knowledge O
could O
advance RARE
diagnosis O
and O
treatment O
of O
the O
patient O
and O
counseling RARE
of O
the O
affected O
family O
. O

Here O
we O
show O
that O
independent O
of O
uncertainties RARE
in O
the O
models O
, O
terrestrial RARE
planets RARE
with O
dense RARE
atmosphere RARE
like O
Venus RARE
can O
evolve RARE
into O
one O
of O
only O
four O
possible O
rotation RARE
states O
. O

Our O
results O
suggest O
that O
WASP ALLCAPS
activates O
transcription O
following O
TCR I-GENE
stimulation O
in O
a O
manner O
that O
is O
independent O
of O
its O
role O
in O
Arp2 NUMERIC
/ O
3 O
- O
directed O
actin I-GENE
polymerization RARE
. O

In O
contrast O
, O
the O
ubiquitous O
expression O
of O
p19 NUMERIC
( O
INK4d NUMERIC
) O
has O
not O
been O
previously O
described O
in O
human O
or O
murine O
B O
- O
lineage O
cells O
. O

This O
animal O
model O
of O
dystonia RARE
appears O
to O
be O
a O
model O
of O
NAD ALLCAPS
in O
man O
from O
the O
viewpoint RARE
of O
treatment O
- O
response O
. O

These O
results O
indicate O
that O
evaluation O
of O
exposure O
to O
S O
. O
neurona RARE
by O
WB ALLCAPS
analysis O
of O
serum O
may O
be O
misleading RARE
in O
young O
horses O
. O

The O
Delta6CCI NUMERIC
virus O
was O
extremely O
attenuated O
in O
replication O
capacity O
yet O
retained O
infectiousness RARE
for O
CEMx174 NUMERIC
and O
MT4 NUMERIC
cells O
. O

OBJECTIVE O
: O
To O
determine O
the O
association O
of O
depressive RARE
symptoms O
with O
HIV O
- O
related O
mortality O
and O
decline O
in O
CD4 I-GENE
lymphocyte I-GENE
counts O
among O
women O
with O
HIV O
. O

Phase O
II O
study O
of O
paclitaxel RARE
and O
oral O
etoposide RARE
in O
patients O
with O
locally O
advanced O
or O
metastatic O
non O
- O
small O
cell O
lung O
cancer O
. O

Analyses RARE
revealed O
that O
scale O
matters RARE
above O
and O
beyond O
the O
effect O
of O
quadrat RARE
area O
. O

Rind RARE
et O
al O
.' RARE
s O
study O
' O
s O
main O
conclusions O
were O
not O
supported O
by O
the O
original O
data O
. O

Not RARE
Available RARE

Lactate RARE
accumulation O
peak O
was O
unaffected O
by O
supplementation O
( O
HMB ALLCAPS
, O
8 O
. O
1 O
+/- O
1 O
. O
1 O
mM O
; O
LEU ALLCAPS
, O
6 O
. O
2 O
+/- O
0 O
. O
8 O
mM O
; O
CON ALLCAPS
, O
7 O
. O
5 O
+/- O
1 O
. O
3 O
mM O
). O

However O
, O
the O
abi1 NUMERIC
- O
1 O
gene O
product O
has O
no O
effect O
on O
the O
ABA O
suppression O
of O
a O
GA ALLCAPS
- O
responsive O
alpha I-GENE
- I-GENE
amylase I-GENE
gene I-GENE
. O

Polyclonal RARE
antibodies O
against O
the O
N O
- O
terminal O
part O
( O
amino O
acids O
12 O
- O
363 NUMERIC
) O
and O
the O
C O
- O
terminal O
part O
( O
amino O
acids O
330 NUMERIC
- O
730 NUMERIC
) O
of O
rainbow RARE
trout O
HIF I-GENE
- I-GENE
1alpha I-GENE
protein I-GENE
recognized O
rainbow RARE
trout O
and O
chinook RARE
salmon RARE
HIF I-GENE
- I-GENE
1alpha I-GENE
protein I-GENE
in O
Western O
blot O
analysis O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
somatic O
cell O
hybrids O
showed O
that O
endothelial O
- O
TACC ALLCAPS
- O
related O
cDNA O
maps O
to O
chromosome O
10 O
. O

PABP ALLCAPS
is O
a O
modular RARE
protein O
, O
with O
four O
N O
- O
terminal O
RNA O
- O
binding O
domains O
and O
an O
extensive O
C O
terminus O
. O

9 O
. O
7 O
( O
95 O
% O
CI O
: O
9 O
. O
6 O
- O
9 O
. O
7 O
) O
micromol RARE
/ O
L O
among O
women O
( O
P O
= O
0 O
. O
003 NUMERIC
). O

The O
mean O
waiting RARE
time O
to O
receive O
the O
pancreas O
transplant O
was O
244 NUMERIC
days O
for O
SPK ALLCAPS
and O
167 NUMERIC
days O
for O
PAK ALLCAPS
recipients O
( O
P O
= O
0 O
. O
001 O
). O

Zarix RARE
expected O
patient O
enrollment RARE
in O
Canadian RARE
clinical O
sites O
to O
begin O
in O
Spring RARE
2001 NUMERIC
[ O
397955 NUMERIC
], O
[ O
405928 NUMERIC
]. O

The O
isoform O
, O
designated O
HDAC9a NUMERIC
, O
is O
132 O
aa O
shorter O
at O
the O
C O
terminus O
than O
HDAC9 NUMERIC
. O

Long RARE
- O
range O
comparison O
of O
human O
and O
mouse O
SCL ALLCAPS
loci I-GENE
: O
localized O
regions O
of O
sensitivity O
to O
restriction O
endonucleases RARE
correspond O
precisely O
with O
peaks O
of O
conserved O
noncoding O
sequences O
. O

In O
Saccharomyces O
cerevisiae O
, O
eIF6 NUMERIC
is O
encoded O
by O
a O
single O
- O
copy O
essential O
gene O
. O

Three O
patients O
received O
additional O
cycles O
of O
5 O
- O
fluorouracil O
+/- O
leucovorin RARE
as O
maintenance O
chemotherapy O
. O
RESULTS O
: O
Thirty O
males O
and O
21 O
females O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
31 O
-- O
73 O
years O
) O
were O
treated O
. O

RESULTS O
: O
Within O
7 O
days O
, O
all O
groups O
re O
- O
acquired O
responding O
for O
heroin RARE
under O
CRF ALLCAPS
at O
rates O
similar O
to O
their O
pre O
- O
lesion O
performance O
. O

The O
application O
of O
the O
biotechnology RARE
at O
the O
plants O
for O
treatment O
of O
the O
surface O
storm RARE
waters RARE
from O
the O
industrial RARE
zone O
Telychka RARE
of O
the O
city RARE
of O
Kyiv RARE
has O
allowed O
the O
content O
of O
petroleum RARE
in O
water O
dropped RARE
to O
the O
Dnieper RARE
to O
be O
constantly RARE
reduced O
50 O
- O
100 O
times O
. O

Using O
immunochemical RARE
co O
- O
precipitation O
methods O
, O
we O
also O
found O
that O
the O
two O
proteins O
are O
bound O
in O
vivo O
. O

Utility RARE
of O
OAE ALLCAPS
screener RARE
( O
GSI ALLCAPS
70 O
) O
for O
the O
evaluation O
of O
distortion RARE
product O
otoacoustic RARE
emissions RARE
] O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
ability O
of O
the O
OAE ALLCAPS
screener RARE
GSI ALLCAPS
70 O
to O
evaluate O
of O
cochlea RARE
function O
in O
neonates O
, O
infants O
and O
adults O
. O

Our O
results O
demonstrated O
that O
50 O
% O
of O
the O
hepatic O
artery O
- O
alone O
ALT ALLCAPS
graft O
showed O
almost O
normal O
structure O
histologically O
at O
1 O
month O
after O
grafting RARE
, O
with O
bile O
secretion O
preserved RARE
. O

Mean O
Hg O
concentrations O
in O
the O
livers RARE
of O
mice O
at O
some O
sites O
in O
Isle RARE
Royale RARE
are O
not O
significantly O
lower O
( O
P O
= O
0 O
. O
62 O
) O
than O
Hg O
concentrations O
considered O
by O
some O
government RARE
agencies RARE
to O
be O
unhealthy RARE
for O
human O
consumption O
. O

We O
show O
here O
that O
the O
in O
vitro O
transcription O
extract O
contains O
a O
binding O
activity O
that O
is O
specific O
for O
the O
initiator O
element O
and O
thus O
may O
participate O
in O
recruiting RARE
RNA O
polymerase O
II O
to O
the O
SL ALLCAPS
RNA I-GENE
gene I-GENE
promoter I-GENE
. O

The O
desirability RARE
function O
is O
based O
on O
the O
search O
for O
a O
global O
optimum RARE
[ O
D O
= O
f RARE
( O
Y1 NUMERIC
, O
Y2 NUMERIC
, O
..., RARE
Yn RARE
)] O
by O
the O
transformation O
of O
the O
measured O
property RARE
to O
a O
dimensionless RARE
scale O
for O
each O
criterion O
. O

Naltrexone RARE
hydrochloride RARE
is O
a O
synthetic O
opioid O
receptor O
antagonist O
recently O
used O
in O
efforts RARE
to O
provide O
rapid O
opioid O
detoxification RARE
. O

We O
mapped O
the O
DGCR6 NUMERIC
gene I-GENE
to O
chromosome O
22q11 NUMERIC
within O
a O
low O
copy O
repeat O
, O
termed O
sc11 NUMERIC
. O
1a NUMERIC
, O
and O
identified O
a O
second O
copy O
of O
the O
gene O
, O
DGCR6L NUMERIC
, O
within O
the O
duplicate RARE
locus O
, O
termed O
sc11 NUMERIC
. O
1b NUMERIC
. O

Proliferative RARE
vasculopathy RARE
and O
cutaneous O
hemorrhages RARE
in O
porcine O
neonates O
infected O
with O
the O
porcine O
reproductive O
and O
respiratory O
syndrome O
virus O
. O

The O
child O
left O
behind O
. O

Using O
the O
two O
- O
hybrid O
system O
, O
we O
show O
that O
nonprenylated RARE
Rac1 I-GENE
interacts O
very O
weakly O
with O
Rho I-GENE
- I-GENE
GDI ALLCAPS
, O
pointing RARE
to O
the O
predominant O
role O
of O
protein O
- O
isoprene RARE
interaction O
in O
complex O
formation O
. O

In O
contrast O
, O
neither O
I O
. O
argentina RARE
nor O
I O
. O
theezans RARE
exerted RARE
any O
effect O
on O
BF O
or O
intestinal O
propulsion RARE
. O

The O
region O
containing O
both O
serines RARE
is O
homologous O
to O
the O
N O
- O
terminal O
destruction RARE
box O
of O
IkappaBalpha I-GENE
, O
- O
beta O
, O
and O
- O
epsilon O
. O

No O
dominant O
clinical O
factor O
of O
risk O
was O
found O
, O
but O
multiple O
regression O
analysis O
identified O
age O
, O
body O
surface O
area O
, O
valve O
size O
, O
shop RARE
order O
fracture O
rate O
, O
and O
manufacturing RARE
period O
as O
risk O
factors O
for O
OSF ALLCAPS
. O

A O
novel O
growth O
- O
related O
nuclear O
protein O
binds O
and O
inhibits O
rat O
aldolase RARE
B O
gene O
promoter O
. O

Northern O
blot O
analysis O
revealed O
that O
mlt RARE
1 O
is O
normally O
expressed O
in O
brain O
, O
spleen O
, O
stom RARE
ach RARE
, O
and O
liver O
. O

NO O
metabolites O
were O
determined O
by O
the O
measurement O
of O
nitrate O
/ O
nitrite RARE
( O
NOx RARE
, O
micromol RARE
/ O
mmol O
creatinine O
) O
and O
cyclic O
guanosine RARE
monophosphate O
( O
cGMP RARE
, O
nmol O
/ O
mmol O
creatinine O
) O
in O
plasma O
and O
urine O
. O

As O
a O
complement O
to O
genome O
- O
wide O
mapping O
and O
sequencing O
efforts RARE
, O
it O
is O
often O
important O
to O
generate O
detailed O
maps O
and O
sequence O
data O
for O
specific O
regions O
of O
interest O
. O

The O
observed O
phenotypes O
may O
be O
explained O
by O
( O
i O
) O
a O
selective O
disruption O
of O
very O
- O
low O
- O
density O
lipoprotein O
secretion O
due O
to O
decreased O
expression O
of O
genes O
encoding O
apolipoprotein I-GENE
B I-GENE
and O
microsomal RARE
triglyceride RARE
transfer O
protein O
, O
( O
ii O
) O
an O
increase O
in O
hepatic O
cholesterol O
uptake O
due O
to O
increased O
expression O
of O
the O
major O
high O
- O
density O
lipoprotein O
receptor O
, O
scavenger RARE
receptor I-GENE
BI ALLCAPS
, O
and O
( O
iii O
) O
a O
decrease O
in O
bile O
acid O
uptake O
to O
the O
liver O
due O
to O
down O
- O
regulation O
of O
the O
major O
basolateral RARE
bile O
acid O
transporters I-GENE
sodium O
taurocholate RARE
cotransporter RARE
protein I-GENE
and O
organic O
anion RARE
transporter I-GENE
protein I-GENE
1 I-GENE
. O

Effects O
of O
aerosol RARE
- O
vapor RARE
JP ALLCAPS
- I-GENE
8 I-GENE
jet RARE
fuel RARE
on O
the O
functional O
observational RARE
battery O
, O
and O
learning O
and O
memory O
in O
the O
rat O
. O

In O
mouse O
, O
Mmip1 NUMERIC
( O
Mad RARE
member O
interacting O
protein O
1 O
) O
and O
Smc3 NUMERIC
share O
99 O
% O
sequence O
identity O
and O
are O
products O
of O
the O
same O
gene O
. O

To O
identify O
the O
important O
cis O
- O
DNA O
regulatory O
element O
( O
s O
) O
involved O
in O
the O
tissue O
-, O
region O
-, O
and O
cell O
- O
specific O
expression O
of O
the O
mE LASTCAP
- I-GENE
RABP ALLCAPS
gene I-GENE
, O
the O
5 O
- O
kb O
DNA O
fragment O
was O
sequenced O
. O

Regional RARE
blood O
blow RARE
was O
measured O
by O
means O
of O
microspheres O
in O
predefined RARE
regions O
of O
the O
C6 O
, O
T11 NUMERIC
, O
and O
L6 NUMERIC
vertebrae RARE
. O

Breast RARE
cancer O
risk O
assessment O
: O
Who RARE
holds RARE
the O
magic RARE
crystal O
ball RARE
? O

The O
frameshift O
initiated O
by O
ADEx2 NUMERIC
is O
believed O
to O
alter O
the O
regular O
coding O
sequence O
, O
acting O
as O
a O
loss O
- O
of O
- O
function O
ASIP ALLCAPS
mutation O
. O

CONCLUSIONS O
: O
Adding RARE
MMF ALLCAPS
, O
a O
potent O
topical RARE
corticosteroid O
, O
to O
an O
emollient RARE
cream O
is O
statistically O
significantly O
more O
effective O
than O
emollient RARE
cream O
alone O
in O
reducing O
acute O
radiation O
dermatitis O
. O

Copyright O
2001 NUMERIC
Academic O
Press O
. O

CONCLUSIONS O
: O
Although O
the O
levels O
of O
oxLDL RARE
antibodies O
might O
be O
modified O
in O
early O
hypertension O
, O
once O
advanced O
coronary O
artery O
disease O
has O
developed O
the O
presence O
of O
hypertension O
does O
not O
affect O
anti O
- O
oxLDL RARE
levels O
. O

As O
an O
application O
of O
reverse O
genetics RARE
, O
we O
introduced O
one O
nucleotide O
change O
( O
UCU ALLCAPS
to O
ACU ALLCAPS
) O
to O
immediate O
downstream O
of O
the O
RNA O
- O
editing RARE
site O
of O
the O
V O
gene O
in O
the O
full O
- O
length O
hPIV2 NUMERIC
cDNA O
and O
were O
able O
to O
obtain O
infectious O
viruses O
[ O
rPIV2V NUMERIC
(-)] RARE
from O
the O
cDNA O
. O

At O
both O
companies RARE
sites O
Salmonella RARE
enteritidis RARE
and O
Salmonella RARE
typhimurium RARE
Tr104 NUMERIC
were O
also O
isolated O
occasionally RARE
from O
various O
locations O
. O

Most O
yeast O
peroxisomal RARE
matrix O
proteins O
contain O
a O
type O
1C NUMERIC
- O
terminal O
peroxisomal RARE
targeting O
signal O
( O
PTS1 NUMERIC
) O
consisting O
of O
the O
tripeptide RARE
SKL ALLCAPS
or O
a O
conservative O
variant O
thereof RARE
. O

Tumor RARE
- O
like O
accumulation O
on O
Tl O
- O
201 O
SPECT O
in O
subacute O
hemorrhagic O
cerebral O
infarction O
. O

WRN ALLCAPS
helicase I-GENE
resolves RARE
alternate O
DNA O
structures O
including O
tetraplex RARE
and O
triplex RARE
DNA O
, O
and O
Holliday RARE
junctions O
. O

The O
increase O
in O
number O
of O
terminal O
hairs RARE
, O
which O
are O
defined O
as O
hairs RARE
more O
than O
60 O
microm O
in O
diameter O
, O
in O
the O
designated O
area O
( O
0 O
. O
5 O
cm O
square O
= O
0 O
. O
25 O
cm2 O
area O
) O
of O
the O
procyanidin RARE
B O
- O
2 O
group O
subjects O
after O
the O
6 O
- O
month O
trial O
was O
significantly O
greater O
than O
that O
of O
the O
placebo O
control O
group O
subjects O
( O
procyanidin RARE
B O
- O
2 O
, O
1 O
. O
99 O
+/- O
2 O
. O
58 O
( O
mean O
+/- O
SD O
)/ O
0 O
. O
25 O
cm2 O
; O
placebo O
, O
- O
0 O
. O
82 O
+/- O
3 O
. O
40 O
( O
mean O
+/- O
SD O
)/ O
0 O
. O
25 O
cm2 O
; O
P O
< O
0 O
. O
02 O
, O
two O
- O
sample O
t O
test O
). O

SKP1 NUMERIC
- O
SnRK RARE
protein O
kinase O
interactions O
mediate O
proteasomal RARE
binding O
of O
a O
plant O
SCF ALLCAPS
ubiquitin I-GENE
ligase I-GENE
. O

Based O
on O
the O
hypothesis O
that O
evolutionarily O
conserved O
regions O
are O
functionally O
important O
and O
likely O
to O
interact O
with O
coactivators RARE
, O
we O
compared O
the O
amino O
acid O
sequence O
of O
C O
/ O
EBPalpha RARE
from O
different O
species O
( O
frog RARE
to O
human O
) O
and O
identified O
four O
highly O
conserved O
regions O
( O
CR1 NUMERIC
- O
CR4 NUMERIC
) O
within O
the O
transactivation O
domain O
. O

Colorectal RARE
cancer O
was O
shown O
to O
disproportionately RARE
overburden RARE
Ashkenazi RARE
Jews RARE
, O
who O
may O
also O
be O
at O
increased O
risk O
for O
ovarian O
, O
pancreatic O
and O
stomach O
cancer O
, O
and O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Percentages RARE
of O
recovery O
for O
overload O
and O
dilution O
tests O
were O
between O
87 O
and O
120 O
%. O

This O
shows O
that O
in O
situations O
of O
separated O
breaks RARE
, O
NHEJ ALLCAPS
deficiency O
leads O
to O
genomic O
rearrangements O
, O
in O
agreement O
with O
chromosomal O
studies O
. O

Copyright O
2001 NUMERIC
S O
. O

After O
nerve O
injury O
, O
the O
nociceptive RARE
responses O
through O
type O
I O
neurons O
, O
which O
are O
polymodal RARE
C O
- O
fibers O
and O
drive O
NK1 NUMERIC
- O
receptor I-GENE
mechanisms O
in O
spinal O
pain O
transmission O
, O
were O
completely O
lost O
, O
but O
without O
changes O
in O
type O
II O
ones O
, O
which O
are O
polymodal RARE
C O
- O
fibers O
and O
drive O
NMDA ALLCAPS
receptor I-GENE
- I-GENE
mechanisms O
, O
while O
type O
III O
ones O
, O
which O
are O
capsaicin RARE
- O
insensitive RARE
( O
possibly O
A O
- O
fibers O
) O
and O
drive O
NMDA ALLCAPS
- O
receptor I-GENE
mechanisms O
, O
were O
markedly O
enhanced O
. O

SV1 NUMERIC
has O
a O
33 O
- O
amino O
acid O
insert O
in O
the O
S1 I-GENE
transmembrane I-GENE
domain I-GENE
that O
does O
not O
alter O
S1 I-GENE
overall O
hydrophobicity RARE
, O
but O
makes O
the O
S0 NUMERIC
- O
S1 I-GENE
linker O
longer O
. O

A O
variety O
of O
receptor O
- O
mediated O
signaling O
pathways O
are O
controlled O
by O
both O
positive O
and O
negative O
extracellular O
regulators O
. O

A O
20 O
- O
base O
pair O
oligonucleotide O
containing O
this O
nonamer RARE
confers O
up O
- O
regulation O
by O
hypoxia O
and O
inhibition O
by O
unsaturated RARE
fatty O
acids O
when O
placed O
upstream O
of O
a O
heterologous O
promoter O
in O
a O
lacZ I-GENE
reporter I-GENE
construct I-GENE
. O

Our O
results O
indicate O
that O
D O
( O
4 O
) O
and O
D O
( O
2L NUMERIC
) O
receptors O
activate O
the O
ERK I-GENE
kinase I-GENE
cascade O
by O
first O
mobilizing RARE
signaling O
by O
the O
PDGF I-GENE
receptor I-GENE
, O
followed O
by O
the O
subsequent O
activation O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
by O
pathways O
associated O
with O
this O
receptor O
tyrosine O
kinase I-GENE
. O

Raes RARE
, O
P O
. O

Finally O
, O
we O
compared O
the O
differential O
screening O
techniques O
in O
terms O
of O
sensitivity O
, O
efficiency O
and O
occurrence O
of O
false O
positives RARE
. O

C O
/ O
EBPbeta I-GENE
LIP ALLCAPS
overexpressing O
HC11 NUMERIC
cells O
did O
not O
express O
beta O
- O
casein I-GENE
mRNA I-GENE
( O
mammary O
epithelial O
cell O
differentiation O
marker O
) O
in O
response O
to O
lactogenic RARE
hormones O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
is O
involved O
in O
the O
regulation O
of O
CD154 NUMERIC
( O
CD40 I-GENE
ligand O
) O
expression O
in O
primary O
human O
T O
cells O
. O

Subacute RARE
diencephalic RARE
angioencephalopathy RARE
( O
SDAE ALLCAPS
) O
is O
a O
rare O
and O
fatal O
disease O
of O
unknown O
etiology O
that O
involves O
the O
thalami RARE
bilaterally RARE
. O

NGF ALLCAPS
elicits RARE
a O
more O
delayed O
and O
sustained O
ERK I-GENE
phosphorylation O
than O
EGF I-GENE
, O
consistent O
with O
previous O
reports O
. O

TBARS ALLCAPS
levels O
, O
oxygen O
- O
radical O
absorbing RARE
capacity O
assay O
and O
AFR ALLCAPS
release O
assessed O
by O
electron O
paramagnetic RARE
resonance O
( O
EPR ALLCAPS
) O
were O
used O
to O
explore O
the O
existence O
of O
oxidative O
stress O
in O
diabetes O
. O

Pulmonary RARE
vein O
varix RARE
in O
association O
with O
bilateral O
pulmonary O
vein O
stenosis O
. O

Derivation RARE
and O
initial O
characterization O
of O
a O
mouse O
mammary O
tumor O
cell O
line O
carrying O
the O
polyomavirus RARE
middle O
T O
antigen I-GENE
: O
utility RARE
in O
the O
development O
of O
novel O
cancer O
therapeutics RARE
. O

The O
images O
showed O
rapid O
, O
predominantly O
urinary O
excretion O
of O
99mTc O
ciprofloxacin RARE
, O
with O
low O
to O
absent O
brain O
, O
lung O
and O
bone O
marrow O
uptake O
and O
low O
liver O
uptake O
and O
excretion O
. O

Thus O
, O
the O
anti O
- O
interferon I-GENE
functions O
of O
vIRF RARE
- O
2 O
may O
contribute O
to O
the O
establishment O
of O
a O
chronic O
or O
latent O
infection O
. O

Topological RARE
and O
mutational O
analysis O
of O
Saccharomyces O
cerevisiae O
Ste14p NUMERIC
, O
founding RARE
member O
of O
the O
isoprenylcysteine RARE
carboxyl O
methyltransferase RARE
family O
. O

Two O
remotely RARE
situated O
exons O
within O
the O
complement O
C3 I-GENE
gene I-GENE
locus I-GENE
encode O
an O
alternate O
5 O
' O
end O
and O
proximal O
ORF O
under O
the O
control O
of O
a O
bidirectional RARE
promoter O
. O

Although O
there O
was O
a O
high O
correlation O
between O
sap RARE
flux RARE
densities RARE
registered RARE
by O
the O
old O
and O
new O
sensors RARE
, O
significant O
differences O
in O
sap RARE
flux RARE
densities RARE
between O
the O
duplicated O
sensors RARE
were O
detected O
. O

Their O
numbers O
have O
regularly RARE
increased O
since O
the O
mid O
- O
1970s NUMERIC
. O

The O
hcKrox RARE
gene I-GENE
family I-GENE
regulates O
multiple O
extracellular O
matrix O
genes O
. O

NB ALLCAPS
- O
506 NUMERIC
completely O
inhibits O
the O
capacity O
of O
topoisomerase I-GENE
I I-GENE
to O
phosphorylate O
, O
in O
vitro O
, O
the O
human O
splicing O
factor O
2 O
/ O
alternative O
splicing O
factor O
( O
SF2 NUMERIC
/ O
ASF ALLCAPS
). O

Recent O
studies O
using O
isolated O
rat O
adipocytes O
and O
chemically RARE
synthesized O
PIG ALLCAPS
compounds O
point O
to O
IRS1 NUMERIC
/ O
3 O
tyrosine O
phosphorylation O
by O
p59Lyn NUMERIC
kinase I-GENE
as O
the O
site O
of O
cross O
- O
talk RARE
, O
the O
negative O
regulation O
of O
which O
by O
interaction O
with O
caveolin RARE
is O
apparently O
abrogated O
by O
PIG ALLCAPS
. O

To O
investigate O
the O
effects O
of O
exogenous O
hyaluronic RARE
acid O
, O
the O
development O
of O
port RARE
- O
site O
metastasis O
was O
examined O
using O
mouse O
adenocarcinoma O
cell O
- O
line O
colon O
26 O
cells O
. O

METHODS O
: O
Thyroid RARE
status O
was O
measured O
at O
baseline O
( O
1990 O
- O
93 O
), O
through O
assessment O
of O
serum O
antibodies O
to O
thyroid O
peroxidase I-GENE
( O
TPO ALLCAPS
- O
Abs RARE
, O
positive O
: O
> O
10 O
IU O
/ O
ml O
), O
serum O
TSH I-GENE
levels O
, O
and O
when O
TSH I-GENE
was O
abnormal O
(< O
0 O
. O
4 O
or O
> O
4 O
. O
0 O
mU LASTCAP
/ O
l O
), O
serum O
thyroxin RARE
levels O
( O
T4 O
). O

Mechanical RARE
ventilation O
in O
control O
lungs O
produced O
a O
47 O
% O
decrease O
in O
chord RARE
compliance O
, O
an O
increase O
in O
lung O
lavage RARE
levels O
of O
tumor O
necrosis O
factor O
( O
TNF I-GENE
)- I-GENE
alpha I-GENE
( O
722 NUMERIC
+/- O
306 NUMERIC
pg O
/ O
ml O
), O
interleukin I-GENE
( O
IL I-GENE
)- I-GENE
1beta I-GENE
( O
902 NUMERIC
+/- O
322 NUMERIC
pg O
/ O
ml O
), O
and O
macrophage O
inflammatory O
protein O
- O
2 O
( O
MIP ALLCAPS
- O
2 O
) O
( O
363 NUMERIC
+/- O
104 O
pg O
/ O
ml O
) O
as O
compared O
with O
low O
levels O
of O
cytokines O
detected O
in O
preventilation RARE
data O
, O
and O
no O
change O
in O
percentage O
of O
surfactant O
large O
aggregates O
( O
LA O
). O

Autoregulation RARE
enables O
different O
pathways O
to O
control O
CCAAT O
/ O
enhancer O
binding O
protein O
beta O
( O
C O
/ O
EBP I-GENE
beta I-GENE
) O
transcription O
. O

In O
the O
past O
decade RARE
, O
there O
have O
been O
enormous RARE
advances RARE
in O
the O
use O
of O
Bayesian RARE
methodology RARE
for O
analysis O
of O
epidemiologic RARE
data O
, O
and O
there O
are O
now O
many O
practical RARE
advantages O
to O
the O
Bayesian RARE
approach O
. O

In O
strains O
lacking O
tup11 NUMERIC
and O
tup12 NUMERIC
, O
the O
atf1 NUMERIC
- O
pcr1 NUMERIC
transcriptional O
activator O
continues RARE
to O
play O
a O
central O
role O
in O
fbp1 NUMERIC
- O
lacZ I-GENE
expression O
; O
however O
, O
spc1 NUMERIC
MAPK I-GENE
phosphorylation O
of O
atf1 NUMERIC
is O
no O
longer O
essential O
for O
its O
activation O
. O

Single RARE
amino O
acid O
substitutions O
at O
the O
acyl RARE
- O
CoA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
interrupt RARE
14 O
[ O
C O
] O
palmitoyl RARE
- O
CoA I-GENE
binding I-GENE
of O
ACBP2 NUMERIC
, O
an O
Arabidopsis O
acyl RARE
- O
CoA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with O
ankyrin RARE
repeats O
. O

RESULTS O
: O
Sixty RARE
per O
cent O
of O
African O
Americans RARE
exposed O
in O
26 O
community O
outbreaks RARE
were O
TST ALLCAPS
positive O
compared O
to O
only O
40 O
% O
of O
whites RARE
following O
comparable O
exposures O
. O

For O
immunological RARE
methods O
, O
identification O
of O
such O
antigens O
with O
intermolecular RARE
variability O
, O
e O
. O
g O
., O
the O
structural O
aescin RARE
analogs RARE
, O
is O
of O
unknown O
validity O
. O

It O
was O
found O
that O
intrathecal RARE
administration O
( O
i O
. O
t O
.) O
of O
D2 I-GENE
receptor I-GENE
agonist O
LY171555 NUMERIC
or O
D1 NUMERIC
/ O
D2 NUMERIC
receptor I-GENE
agonist O
apomorphine RARE
increased O
pain O
threshold O
and O
had O
a O
potentiating RARE
effect O
on O
AA O
. O

Interactions RARE
between O
the O
checkpoint O
abrogator RARE
UCN ALLCAPS
- I-GENE
01 O
and O
several O
pharmacological O
inhibitors O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) I-GENE
kinase I-GENE
( O
MEK I-GENE
)/ O
MAPK I-GENE
pathway O
have O
been O
examined O
in O
a O
variety O
of O
human O
leukemia O
cell O
lines O
. O

Analysis O
of O
regulatory O
regions O
in O
the O
promoter O
of O
the O
ctr4 NUMERIC
(+) RARE
copper O
transporter RARE
gene I-GENE
in O
fission O
yeast O
Schizosaccharomyces O
pombe O
reveals O
the O
identity O
of O
a O
conserved O
copper O
- O
signaling O
element O
( O
CuSE RARE
), O
which O
is O
recognized O
by O
the O
transcription O
factor O
Cuf1 NUMERIC
. O

However O
, O
during O
our O
work O
with O
a O
replication O
- O
deficient O
virus O
expressing O
the O
ASF ALLCAPS
/ O
SF2 NUMERIC
splicing O
factor I-GENE
from O
a O
progesterone O
antagonist O
- O
inducible O
gene O
cassette O
, O
we O
discovered O
that O
ASF ALLCAPS
/ O
SF2 NUMERIC
was O
expressed O
at O
a O
significant O
level O
in O
the O
293 O
producer RARE
cell O
line O
, O
even O
in O
the O
absence O
of O
inducer RARE
. O

This O
study O
suggests O
that O
PSP ALLCAPS
is O
more O
common O
than O
previously O
considered O
, O
is O
commonly O
misdiagnosed RARE
and O
that O
the O
majority O
of O
cases O
are O
not O
initially O
referred O
to O
neurologists RARE
. O

Between RARE
1967 NUMERIC
and O
1994 O
, O
495 NUMERIC
patients O
underwent O
surgery O
for O
primary O
PTC ALLCAPS
at O
the O
Department RARE
of O
Surgery RARE
, O
Helsinki RARE
University O
Central RARE
Hospital RARE
. O

The O
described O
results O
show O
that O
DTD ALLCAPS
is O
fast O
, O
simple O
, O
and O
easy RARE
to O
automate RARE
; O
requires O
only O
a O
small O
amount O
of O
sample O
( O
approximately O
50 O
mg O
); O
and O
affords RARE
quantitative O
information O
about O
the O
main O
groups O
of O
compounds O
present O
in O
cheeses RARE
. O

Srb10 NUMERIC
is O
a O
physiological O
regulator O
of O
Gcn4 NUMERIC
stability O
because O
both O
phosphorylation O
and O
turnover O
of O
Gcn4 NUMERIC
are O
diminished O
in O
srb10 NUMERIC
mutants I-GENE
. O

The O
promoter O
activity O
of O
the O
proximal O
region O
was O
found O
to O
be O
restricted O
to O
a O
subset O
of O
prestalk RARE
cells O
. O

Two O
nuclear O
medicine O
physicians O
blinded RARE
to O
the O
surgical O
findings O
interpreted O
all O
available O
images O
and O
various O
Tc O
- O
99m O
MIBI ALLCAPS
image O
combinations O
at O
15 O
minutes O
alone O
; O
15 O
minutes O
and O
2 O
hours O
, O
15 O
minutes O
and O
4 O
hours O
; O
and O
15 O
minutes O
and O
2 O
and O
4 O
hours O
each O
with O
and O
without O
correlative RARE
pertechnetate RARE
thyroid O
imaging O
. O

We O
demonstrated O
that O
, O
under O
serum O
- O
starved RARE
conditions O
, O
KMS ALLCAPS
- O
11 O
and O
OPM ALLCAPS
- O
2 O
cells O
express O
appreciable RARE
levels O
of O
phosphorylated O
FGFR3 NUMERIC
mutants I-GENE
indicating O
a O
constitutive O
activation O
of O
the O
Y373C NUMERIC
and O
K650E NUMERIC
receptors I-GENE
; O
the O
addition O
of O
the O
aFGF RARE
ligand O
further O
increased O
the O
level O
of O
receptor O
phosphorylation O
. O

Identical RARE
effects O
were O
obtained O
when O
inhibitors O
and O
dominant O
negative O
mutants O
were O
tested O
on O
the O
- O
29 O
to O
+ O
139 O
bp O
region O
of O
the O
cyclin I-GENE
D1 I-GENE
promoter I-GENE
. O

In O
this O
paper O
the O
tyrosine O
dephosphorylating RARE
enzymes O
, O
the O
protein O
- O
tyrosine O
phosphatases I-GENE
( O
PTPs RARE
), O
are O
studied O
which O
can O
be O
grouped RARE
into O
two O
subfamilies RARE
, O
the O
soluble O
PTPs RARE
and O
the O
receptor O
PTPs RARE
( O
RPTPs RARE
). O

Coexposure RARE
to O
FP ALLCAPS
also O
resulted O
in O
a O
more O
pronounced O
and O
sustained O
activation O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
/ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
protein I-GENE
kinase I-GENE
cascade O
after O
PMA O
treatment O
, O
although O
disruption O
of O
this O
pathway O
by O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
1 I-GENE
inhibitor I-GENE
U0126 NUMERIC
did O
not O
prevent O
potentiation O
of O
apoptosis O
. O

The O
LA O
50s NUMERIC
derived O
from O
this O
combined O
data O
when O
compared O
with O
our O
earlier O
series O
from O
1965 NUMERIC
to O
1970 NUMERIC
also O
did O
not O
show O
a O
significant O
change O
in O
mortality O
. O

Most O
patients O
harboring O
metronidazole RARE
- O
and O
clarithromycin RARE
- O
resistant O
strains O
were O
eradicated RARE
at O
an O
equal O
rate O
by O
each O
of O
the O
three O
regimens O
. O

Responses RARE
of O
single O
- O
unit O
carotid O
body O
chemoreceptors RARE
in O
adult O
rats O
. O

Thus O
, O
MKK7 NUMERIC
is O
an O
essential O
and O
specific O
regulator O
of O
stress O
- O
induced O
SAPK I-GENE
/ I-GENE
JNK I-GENE
activation O
in O
mast O
cells O
and O
MKK7 NUMERIC
negatively O
regulates O
growth O
factor O
and O
antigen I-GENE
receptor I-GENE
- I-GENE
driven O
proliferation O
in O
hematopoietic O
cells O
. O

The O
N O
- O
terminal O
portion O
of O
Notch I-GENE
( O
IC ALLCAPS
) O
inhibited O
p50 I-GENE
DNA I-GENE
binding I-GENE
and O
interacted O
specifically O
with O
p50 I-GENE
subunit I-GENE
, O
not O
p65 I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

To O
account O
for O
this O
observation O
, O
other O
possible O
causes O
include O
increased O
CSF I-GENE
pulsation RARE
in O
children O
creating RARE
motion O
artifact RARE
, O
changes O
in O
arterial O
oxygen O
concentration O
intrinsic O
to O
propofol RARE
or O
related O
to O
the O
supplemental RARE
oxygen O
normally O
administered O
, O
or O
changes O
in O
CSF I-GENE
protein I-GENE
levels O
related O
to O
propofol RARE
binding O
to O
proteins O
for O
uptake O
into O
CSF I-GENE
. O

Molecular O
cloning O
and O
characterization O
of O
OsPSK RARE
, O
a O
gene O
encoding O
a O
precursor O
for O
phytosulfokine RARE
- O
alpha O
, O
required O
for O
rice O
cell O
proliferation O
. O

The O
present O
study O
was O
initiated O
to O
explore O
the O
potential O
of O
a O
hybrid O
biological O
reactor RARE
, O
combining RARE
trickling RARE
filter O
( O
TF I-GENE
) I-GENE
and O
activated O
sludge RARE
process O
( O
ASP ALLCAPS
), O
to O
treat O
wastewater RARE
containing O
trichloroethylene RARE
( O
TCE ALLCAPS
) O
at O
ambient RARE
temperature O
at O
different O
hydraulic RARE
retention O
time O
( O
HRT ALLCAPS
). O

If O
you RARE
think RARE
education O
is O
expensive RARE
-- O
try RARE
ignorance RARE
-- O
Bok RARE
' O
s O
Law RARE
. O

The O
COD ALLCAPS
and O
color O
removals RARE
were O
both O
more O
than O
90 O
% O
when O
FeCl3 NUMERIC
was O
used O
as O
the O
coagulation O
( O
dosages RARE
of O
two O
- O
step O
coagulation O
were O
0 O
. O
031 NUMERIC
and O
0 O
. O
012 NUMERIC
mol O
/ O
L O
respectively O
) O
after O
a O
ferrous RARE
hydrogen O
peroxide RARE
oxidation O
pretreatment O
at O
a O
H2O2 NUMERIC
dosage O
of O
0 O
. O
06 O
mol O
/ O
L O
. O

An O
element O
within O
the O
5 O
' O
untranslated O
region O
of O
human O
Hsp70 NUMERIC
mRNA I-GENE
which O
acts O
as O
a O
general O
enhancer O
of O
mRNA O
translation O
. O

The O
selective O
alteration O
of O
the O
genome O
using O
Cre RARE
recombinase RARE
to O
target O
the O
rearrangement O
of O
genes O
flanked O
by O
LOX ALLCAPS
recognition O
sequences O
has O
required O
the O
use O
of O
two O
separate O
genetic O
constructs O
in O
trans O
, O
one O
containing O
cre RARE
and O
the O
other O
containing O
the O
gene O
of O
interest O
flanked O
by O
LOX ALLCAPS
sites O
. O

It O
has O
been O
suggested O
that O
members O
of O
this O
protein O
family O
exhibit O
both O
prolyl RARE
isomerase I-GENE
and O
chaperone RARE
activity O
. O

Newcastle RARE
disease O
antibody O
titre RARE
is O
dependent O
on O
serum O
calcium O
concentration O
. O

In O
three O
cases O
( O
21 O
. O
4 O
%), O
the O
MR O
imaging O
was O
interpreted O
as O
negative O
, O
but O
microscopic O
tumor O
was O
shown O
around O
seroma RARE
on O
reexcision RARE
. O

2 O
were O
nonviable RARE
, O
and O
the O
mutant O
Vp1s NUMERIC
unexpectedly RARE
failed O
to O
localize O
to O
the O
nucleus O
though O
Vp2 NUMERIC
and O
Vp3 NUMERIC
did O
, O
suggesting O
that O
the O
mutated O
NLS1 NUMERIC
acted RARE
as O
a O
dominant O
signal O
for O
the O
cytoplasmic O
localization O
of O
Vp1 NUMERIC
. O

Compared RARE
with O
normal O
control O
subjects O
, O
all O
74 O
TOF O
patients O
had O
decreased O
systolic O
and O
diastolic O
myocardial O
velocities RARE
and O
a O
longer O
isovolumic RARE
relaxation O
time O
. O

The O
corresponding O
orifice RARE
voltages RARE
for O
the O
three O
instruments O
were O
20 O
/ O
50 O
/ O
80 O
V O
( O
API ALLCAPS
365 NUMERIC
), O
30 O
/ O
90 O
/ O
130 O
V O
( O
API ALLCAPS
2000 O
) O
and O
40 O
/ O
80 O
/ O
120 O
V O
( O
API ALLCAPS
3000 NUMERIC
). O

We O
compared O
previously O
the O
methylation O
status O
between O
normal O
liver O
and O
liver O
tumors O
in O
SV40 O
T O
/ O
t O
antigen I-GENE
transgenic O
mice O
( O
MT ALLCAPS
- O
D2 NUMERIC
mice O
) O
using O
Restriction O
Landmark RARE
Genomic O
Scanning RARE
for O
Methylation RARE
( O
RLGS ALLCAPS
- O
M O
) O
and O
identified O
several O
loci O
/ O
spots O
that O
appeared O
to O
be O
methylated RARE
frequently O
in O
liver O
tumors O
. O

We O
have O
cloned O
a O
novel O
mouse O
protein O
, O
TAF I-GENE
( O
II I-GENE
) I-GENE
140 O
, O
containing O
an O
HFD ALLCAPS
and O
a O
plant O
homeodomain I-GENE
( O
PHD ALLCAPS
) O
finger O
, O
which O
we O
demonstrated O
by O
immunoprecipitation O
to O
be O
a O
mammalian O
TFIID I-GENE
component O
. O

3D NUMERIC
image O
- O
processing O
permits O
to O
analyse RARE
ultrasound O
data O
interactively RARE
in O
three O
orthogonal RARE
planes RARE
( O
section O
mode O
) O
or O
in O
realistic RARE
3D NUMERIC
views RARE
( O
rendering RARE
mode O
). O

A O
proposal RARE
of O
50 O
performance O
indicators O
divided O
into O
five O
different O
groups O
is O
presented O
here O
, O
namely O
structural O
indicators O
, O
operational RARE
indicators O
, O
water O
and O
service RARE
quality O
indicators O
, O
personnel RARE
indicators O
and O
economic RARE
indicators O
. O

These O
analyses O
re O
- O
open O
the O
question O
whether O
all O
the O
CesA RARE
genes O
encode O
cellulose RARE
synthases RARE
or O
whether O
some O
of O
the O
sub O
- O
class O
members O
may O
encode O
other O
non O
- O
cellulosic RARE
( O
1 O
--> O
4 O
) O
beta O
- O
glycan RARE
synthases RARE
in O
plants O
. O

The O
relationship O
of O
the O
factor O
V O
Leiden RARE
mutation O
or O
the O
deletion O
- O
deletion O
polymorphism O
of O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
to O
postoperative O
thromboembolic RARE
events O
following O
total O
joint O
arthroplasty RARE
. O

In O
contrast O
, O
exogenous O
PTHrP1 NUMERIC
- O
34 NUMERIC
and O
1 O
- O
86 O
peptides O
did O
not O
significantly O
affect O
IL I-GENE
- I-GENE
8 I-GENE
production O
; O
moreover RARE
, O
PTHrP RARE
- O
neutralizing RARE
antibodies O
did O
not O
inhibit O
the O
production O
of O
IL I-GENE
- I-GENE
8 I-GENE
by O
transfected O
PTHrP RARE
. O

Furthermore O
, O
this O
kinase I-GENE
- I-GENE
deficient O
mutant I-GENE
inhibited O
2 O
- O
MeSADP RARE
- O
induced O
caspase RARE
- O
3 O
stimulation O
and O
the O
associated O
decrease O
in O
cell O
number O
. O

Against RARE
gram O
- O
positive O
organisms O
, O
E O
- O
4767 NUMERIC
and O
E O
- O
5065 NUMERIC
were O
, O
in O
general O
, O
eight O
- O
and O
fourfold O
more O
active O
than O
tosufloxacin RARE
, O
which O
is O
the O
most O
potent O
of O
the O
reference O
compounds O
. O

The O
results O
presented O
here O
show O
that O
AR1 NUMERIC
of O
the O
promoter O
- O
proximal O
CAP O
subunit O
was O
required O
for O
papBA RARE
transcription O
even O
in O
the O
absence O
of O
the O
histone I-GENE
- I-GENE
like I-GENE
protein I-GENE
H I-GENE
- I-GENE
NS O
. O

CONCLUSIONS O
: O
Under O
current O
immunization O
practices RARE
, O
the O
authors O
estimate O
that O
nearly O
13 O
, O
000 O
Asian RARE
and O
Pacific RARE
Islander RARE
children O
living O
in O
the O
United O
States RARE
today RARE
will O
become O
infected O
with O
HBV O
in O
the O
future O
, O
resulting O
in O
more O
than O
600 O
liver O
carcinoma O
deaths O
. O

METHODS O
: O
A O
structured O
interview RARE
was O
undertaken O
at O
the O
time O
of O
initial O
consultation RARE
and O
at O
subsequent O
1 O
- O
year O
intervals O
regarding O
type O
of O
BHS ALLCAPS
, O
frequency O
of O
spells RARE
, O
associated O
phenomenon O
, O
sequelae RARE
, O
family O
history O
, O
and O
age O
at O
termination O
of O
spells RARE
. O

Cell O
. O

Rapid RARE
evolution O
of O
the O
DNA O
- O
binding O
site O
in O
LAGLIDADG ALLCAPS
homing RARE
endonucleases RARE
. O

These O
mutations O
, O
when O
placed O
in O
a O
wild O
- O
type O
fliF LASTCAP
background O
, O
had O
no O
mutant O
phenotype O
. O

Inhibition O
of O
JNK1 I-GENE
and O
ERK I-GENE
kinase I-GENE
activities O
either O
by O
expression O
of O
the O
dominant O
negative O
mutant O
JNK1 I-GENE
or O
by O
treatment O
with O
a O
selective O
chemical O
inhibitor O
of O
ERK I-GENE
( O
PD098059 NUMERIC
) O
substantially O
abrogates RARE
the O
UV O
induction O
of O
the O
GADD45 NUMERIC
promoter I-GENE
. O

At O
termination O
( O
gd RARE
20 O
), O
confirmed O
- O
pregnant O
females O
( O
21 O
to O
25 O
per O
group O
) O
were O
evaluated O
for O
clinical O
status O
and O
gestational O
outcome O
; O
live O
fetuses RARE
were O
examined O
for O
external O
, O
visceral O
, O
and O
skeletal O
malformations O
. O

In O
mammals O
, O
the O
transcriptional O
repressors RARE
in O
the O
Wnt I-GENE
pathway O
are O
not O
well O
defined O
. O

Intravenous O
L O
- O
carnitine RARE
treatment O
increased O
plasma O
carnitine RARE
concentrations O
, O
improved O
patient O
- O
assessed O
fatigue RARE
, O
and O
may O
prevent O
the O
decline O
in O
peak O
exercise O
capacity O
in O
hemodialysis O
patients O
. O

The O
Van RARE
der RARE
Hoeve RARE
' O
s O
syndrome O
lesions O
as O
poorly O
mineralized RARE
, O
with O
low O
calcium O
salt O
and O
apparent O
increase O
of O
phosphates RARE
. O

A O
computerized O
method O
of O
determining O
the O
focal O
point O
of O
electrical O
activity O
in O
the O
pallidum RARE
of O
parkinsonian RARE
patients O
was O
developed O
using O
on O
- O
line O
quantitative O
physiological O
data O
analysis O
. O

The O
first O
hypothesis O
was O
supported O
in O
the O
sense O
that O
stimulus O
differences O
might O
affect O
behaviour O
even O
without O
their O
successful O
attentive RARE
processing O
in O
normal O
participants RARE
. O

We O
interpret RARE
these O
data O
as O
further O
evidence O
that O
interaction O
with O
a O
small O
GTPase I-GENE
is O
the O
main O
regulatory O
function O
of O
the O
C1 O
domain O
in O
yeast O
. O

This O
effect O
was O
observed O
in O
the O
absence O
of O
de O
novo O
protein O
synthesis O
and O
was O
independent O
of O
histone I-GENE
deacetylase RARE
activity O
. O

Mutation O
analyses O
identified O
the O
cobalt RARE
- O
responsive O
sequences O
as O
the O
stress O
- O
response O
elements O
( O
StREs RARE
). O

In O
order O
to O
quantify RARE
these O
effects O
, O
tests O
were O
conducted O
in O
the O
NASA ALLCAPS
MSFC ALLCAPS
Neutral RARE
Buoyancy RARE
Simulator RARE
, O
in O
the O
NASA ALLCAPS
KC ALLCAPS
- O
135 O
in O
parabolic RARE
flight RARE
, O
and O
in O
space O
with O
the O
EASE ALLCAPS
program O
during O
the O
Shuttle RARE
Atlantis RARE
mission RARE
61 O
- O
B O
. O

OBJECTIVE O
: O
To O
investigate O
the O
association O
between O
complete O
congenital O
heart O
block O
( O
CCHB ALLCAPS
) O
in O
the O
fetus O
and O
adult O
disease O
. O

The O
present O
chemotherapy O
of O
AE ALLCAPS
is O
based O
on O
the O
administration O
of O
benzimidazole RARE
carbamate RARE
derivatives O
, O
such O
as O
mebendazole RARE
and O
albendazole RARE
. O

The O
uptake O
of O
fluorine RARE
- O
18 O
fluorodeoxyglucose RARE
( O
F O
- O
18 O
FDG O
) O
by O
a O
malignant O
tumor O
depends O
on O
the O
blood O
glucose O
level O
. O

Deterministic RARE
effects O
. O

DESIGN O
: O
A O
retrospective O
chart RARE
review O
of O
9 O
, O
322 NUMERIC
patients O
undergoing O
surgical O
procedures O
in O
the O
period O
January O
1993 O
to O
December RARE
1998 O
. O

Peripheral RARE
and O
preemptive RARE
opioid O
antinociception RARE
in O
a O
mouse O
visceral O
pain O
model O
. O

METHODS O
: O
We O
studied O
the O
clinical O
benefit O
of O
depth O
- O
dependent O
RR O
, O
nonuniform RARE
AC O
using O
a O
scanning O
line O
source O
, O
and O
scatter RARE
correction O
( O
photon O
energy O
recovery O
[ O
PER ALLCAPS
]) O
compared O
with O
filtered RARE
backprojection RARE
alone O
. O

Cloning O
and O
characterization O
of O
the O
murine O
beta O
( O
3 O
) O
integrin I-GENE
gene I-GENE
promoter I-GENE
: O
identification O
of O
an O
interleukin I-GENE
- I-GENE
4 I-GENE
responsive I-GENE
element I-GENE
and O
regulation O
by O
STAT I-GENE
- I-GENE
6 I-GENE
. O

DNA O
binding O
assays O
confirmed O
the O
interference O
of O
p30 NUMERIC
( O
II O
) O
with O
the O
assembly O
of O
CREB I-GENE
- I-GENE
Tax I-GENE
- I-GENE
p300 I-GENE
/ I-GENE
CBP I-GENE
multiprotein RARE
complexes I-GENE
on O
21 O
- O
bp O
repeat O
oligonucleotides O
in O
vitro O
. O

Transient O
transfections O
showed O
that O
a O
single O
mutation O
( O
556M NUMERIC
) O
decreased O
TBLV ALLCAPS
enhancer I-GENE
activity O
at O
least O
20 O
- O
fold O
in O
two O
different O
T O
- O
cell O
lines O
. O

In O
conclusion O
, O
tube O
size O
estimated O
by O
Cole RARE
' O
s O
formula O
tends RARE
to O
be O
smaller O
than O
practically RARE
appropriate O
tube O
size O
for O
pediatric O
cardiac O
anesthesia O
, O
and O
therefore O
we O
suggest O
new O
formula O
to O
estimate O
the O
tube O
size O
. O

Thus O
, O
in O
T47D NUMERIC
breast O
carcinoma O
cells O
, O
IL I-GENE
- I-GENE
6 I-GENE
acts O
in O
synergy RARE
with O
EGF I-GENE
receptor I-GENE
autocrine O
activity O
to O
signal O
through O
the O
MAPK I-GENE
/ I-GENE
PI3K NUMERIC
pathways O
. O

Nerve RARE
growth O
factor O
( O
NGF ALLCAPS
) O
and O
retinoic O
acid O
( O
RA O
) O
exert O
important O
actions O
on O
PC12 O
cells O
. O

HexA71 NUMERIC
negatively O
affects O
RpoS RARE
, O
as O
the O
levels O
of O
this O
alternative O
sigma I-GENE
factor I-GENE
are O
higher O
in O
the O
HexA RARE
- O
mutant O
than O
in O
the O
HexA RARE
+ O
strain O
. O

Moreover O
, O
elderly O
men O
with O
bioavailable RARE
estradiol O
levels O
below O
the O
median O
[ O
40 O
pmol RARE
/ O
liter O
( O
11 O
pg O
/ O
ml O
)] O
had O
significantly O
higher O
rates O
of O
bone O
loss O
and O
levels O
of O
bone O
resorption O
markers O
than O
men O
with O
bioavailable RARE
estradiol O
levels O
above O
40 O
pmol RARE
/ O
liter O
. O

The O
histamine O
H1 I-GENE
receptor I-GENE
antagonists O
( O
antihistamines RARE
) O
are O
an O
important O
class O
of O
medications RARE
used O
for O
the O
relief RARE
of O
common O
symptoms O
associated O
with O
hyperhistaminic RARE
conditions O
occurring O
in O
children O
and O
adults O
. O

The O
production O
of O
ceramide RARE
is O
emerging RARE
as O
a O
fixture RARE
of O
programmed O
cell O
death O
. O

The O
flux RARE
rates O
of O
p O
- O
toluidine RARE
decreased O
as O
the O
pH O
value O
in O
the O
donor O
solution O
increased O
. O

Managing RARE
HIV O
. O

BACKGROUND O
: O
There O
is O
increasing O
interest O
on O
the O
part O
of O
investigators RARE
and O
the O
public RARE
at O
large O
in O
finding O
ways O
to O
study O
and O
improve O
treatments O
for O
the O
seriously RARE
mentally RARE
ill RARE
without O
exposing RARE
such O
individuals O
to O
unnecessary RARE
risks RARE
. O

Multidrug RARE
resistance O
in O
Saccharomyces O
cerevisiae O
mainly O
results O
from O
the O
overexpression O
of O
genes O
coding O
for O
the O
membrane O
efflux RARE
pumps RARE
, O
the O
major O
facilitators RARE
and O
the O
ABC ALLCAPS
binding O
cassette O
transporters I-GENE
, O
under O
the O
control O
of O
key O
transcription O
regulators O
encoded O
by O
the O
PDR1 NUMERIC
and O
PDR3 NUMERIC
genes I-GENE
. O

Serum O
PTH I-GENE
tended O
to O
increase O
in O
the O
WL ALLCAPS
group O
but O
not O
in O
the O
WM ALLCAPS
group O
( O
P O
< O
0 O
. O
06 O
). O

Bandshift RARE
experiments O
demonstrate O
that O
BmHR3A NUMERIC
binds O
specifically O
to O
RORE ALLCAPS
( O
Retinoic RARE
acid O
- O
related O
Orphan RARE
receptor I-GENE
Response O
Element RARE
)- O
like O
sequences O
in O
the O
promoters O
of O
both O
genes O
, O
thus O
suggesting O
a O
direct O
role O
for O
BmHR3A NUMERIC
in O
regulating O
the O
expression O
of O
BmGATAbeta RARE
and O
ESP ALLCAPS
genes I-GENE
during O
vitellogenesis RARE
. O

Efficacy RARE
of O
first O
- O
generation O
Cavermap RARE
to O
verify RARE
location O
and O
function O
of O
cavernous RARE
nerves O
during O
radical O
prostatectomy RARE
: O
a O
multi O
- O
institutional RARE
evaluation O
by O
experienced O
surgeons RARE
. O

During O
most O
of O
the O
cell O
cycle O
, O
separase RARE
is O
kept O
inactive O
by O
binding O
to O
an O
inhibitory O
protein O
called O
securin RARE
. O

In O
conclusion O
, O
obesity O
, O
alcohol O
intake O
, O
and O
multimetabolic RARE
disorders O
were O
determined O
to O
be O
independent O
predictors O
for O
the O
development O
of O
hyperuricemia RARE
. O

This O
study O
examined O
the O
role O
of O
cholesteryl RARE
ester O
transfer O
( O
CET ALLCAPS
), O
cholesteryl RARE
ester O
transfer O
protein O
( O
CETP ALLCAPS
) O
activity O
, O
and O
phospholipid O
transfer O
protein O
( O
PLTP ALLCAPS
) O
activity O
in O
the O
increased O
prevalence O
of O
coronary O
artery O
calcification RARE
( O
CAC ALLCAPS
) O
in O
diabetic O
subjects O
compared O
with O
nondiabetic RARE
subjects O
and O
in O
the O
loss O
of O
the O
sex O
difference O
in O
CAC ALLCAPS
in O
diabetes O
. O

In O
the O
mouse O
, O
both O
genes O
reside O
in O
the O
syntenic RARE
region O
8E1 NUMERIC
on O
chromosome O
8 O
. O

We O
observed O
NP O
/ O
NMP4 NUMERIC
/ O
CIZ ALLCAPS
expression O
in O
osteocytes RARE
, O
osteoblasts RARE
, O
and O
chondrocytes RARE
in O
rat O
bone O
. O

Following O
baseline O
clinical O
examination O
and O
initial O
periodontal O
therapy O
, O
32 O
patients O
received O
mucogingival RARE
surgery O
with O
free O
gingival RARE
grafts O
for O
treatment O
of O
insufficient O
attached O
gingiva RARE
. O

In O
contrast O
, O
the O
failure O
of O
the O
QKTT ALLCAPS
motif O
and O
TGN46 NUMERIC
cytoplasmic O
tail O
to O
induce O
steady O
- O
state O
ER O
localization O
of O
vesicular O
stomatitis RARE
virus O
glycoprotein O
( O
VSVG ALLCAPS
) O
chimeras RARE
in O
HeLa O
and O
NRK ALLCAPS
cells O
indicates O
that O
significant O
differences O
in O
early O
secretory O
trafficking O
also O
exist O
. O

We O
previously O
showed O
that O
this O
proteolysis O
1 O
) O
can O
be O
acutely RARE
promoted O
by O
the O
phorbol O
ester O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
), O
2 O
) O
requires O
a O
metalloprotease RARE
activity O
, O
3 O
) O
generates O
both O
shed RARE
GHBP ALLCAPS
and O
a O
membrane O
- O
associated O
GHR ALLCAPS
transmembrane O
/ O
cytoplasmic O
domain O
remnant RARE
, O
and O
4 O
) O
results O
in O
down O
- O
regulation O
of O
GHR ALLCAPS
abundance O
and O
GH I-GENE
signaling O
. O

Our O
data O
indicate O
that O
SIP1 NUMERIC
is O
required O
to O
confine RARE
XBra RARE
gene I-GENE
expression O
to O
the O
mesoderm O
. O

Changes O
of O
the O
DB ALLCAPS
sequence O
without O
affecting O
the O
postulated O
stem O
structure O
led O
to O
drastic RARE
losses RARE
of O
translation O
efficiency O
. O

This O
subfamily O
of O
genes O
all O
have O
a O
single O
ATP O
- O
binding O
domain O
at O
the O
N O
- O
terminus O
and O
a O
single O
C O
- O
terminal O
set O
of O
transmembrane O
segments O
. O

Subsequently RARE
, O
these O
coordinates RARE
must O
be O
interpreted O
to O
define O
particular O
tissues O
and O
organs O
. O

The O
cyclins RARE
bind O
to O
and O
activate O
the O
CDK I-GENE
, O
which O
leads O
to O
phosphorylation O
( O
and O
then O
inhibition O
) O
of O
the O
tumor O
suppressor O
protein O
, O
pRb I-GENE
. O
pRb I-GENE
controls O
commitment RARE
to O
progress O
from O
the O
G1 O
to O
S O
phase O
, O
at O
least O
in O
part O
by O
repressing O
the O
activity O
of O
the O
E2F I-GENE
transcription I-GENE
factors I-GENE
known O
to O
promote O
cell O
proliferation O
. O

The O
mean O
serum O
creatinine O
level O
did O
not O
change O
during O
the O
first O
6 O
months O
after O
withdrawal O
of O
MMF ALLCAPS
. O

The O
severity O
of O
pathologic O
changes O
increased O
with O
the O
magnitude O
of O
percussion RARE
. O

Patients O
with O
antibody O
peaks O
, O
defined O
as O
fivefold RARE
or O
higher O
increase O
in O
antibody O
titer O
compared O
to O
the O
lowest O
antibody O
titer O
over O
the O
course O
of O
GBS ALLCAPS
, O
had O
higher O
disability RARE
scores O
during O
the O
first O
two O
weeks O
of O
GBS ALLCAPS
and O
a O
worse RARE
clinical O
outcome O
( O
anti O
- O
GM1 NUMERIC
IgG I-GENE
and O
anti I-GENE
- I-GENE
GD1a NUMERIC
IgM I-GENE
antibody I-GENE
peaks O
) O
and O
axonal RARE
damage O
( O
anti O
- O
GD1a NUMERIC
IgM I-GENE
antibody I-GENE
peaks O
), O
compared O
to O
patients O
without O
peak O
antibody O
titers RARE
. O

At O
20 O
days O
( O
D O
) O
and O
at O
3 O
months O
post O
- O
TBI ALLCAPS
, O
irradiated O
rats O
had O
a O
significantly O
lower O
percentage O
of O
avoidance RARE
than O
controls O
but O
no O
statistical O
difference O
was O
found O
at O
5 O
months O
post O
- O
TBI ALLCAPS
. O
b O
/ O
Two O
- O
way O
avoidance RARE
test O
: O
this O
test O
was O
performed O
only O
after O
TBI ALLCAPS
. O

TE ALLCAPS
- O
671 NUMERIC
cells O
that O
were O
transfected O
with O
cAMP O
response O
element O
mutant O
constructs O
demonstrated O
a O
diminished O
basal O
activity O
of O
the O
GnRH I-GENE
- I-GENE
II I-GENE
promoter I-GENE
. O

The O
severity O
of O
clinical O
course O
was O
expressed O
by O
means O
of O
SOFA ALLCAPS
score O
( O
group O
A O
0 O
. O
3 O
- O
1 O
- O
1 O
. O
3 O
point O
, O
group O
B O
2 O
. O
2 O
- O
2 O
. O
9 O
- O
2 O
. O
6 O
point O
, O
group O
C O
7 O
. O
4 O
- O
8 O
. O
3 O
- O
7 O
. O
7 O
point O
) O
and O
APACHE ALLCAPS
II I-GENE
score O
( O
group O
A O
3 O
. O
7 O
- O
7 O
. O
6 O
- O
8 O
. O
1 O
point O
, O
group O
B O
8 O
. O
6 O
- O
11 O
. O
1 O
- O
10 O
. O
5 O
point O
, O
group O
C O
16 O
. O
3 O
- O
15 O
. O
2 O
- O
14 O
. O
3 O
point O
). O

A O
novel O
potential O
effector O
of O
M O
- O
Ras I-GENE
and O
p21 I-GENE
Ras I-GENE
negatively O
regulates O
p21 I-GENE
Ras I-GENE
- I-GENE
mediated O
gene I-GENE
induction O
and O
cell O
growth O
. O

Promoter O
transcriptional O
activity O
was O
determined O
for O
a O
wide O
5 O
' O
portion O
of O
the O
human O
annexin RARE
A5 NUMERIC
gene I-GENE
, O
from O
bp O
- O
1275 NUMERIC
to O
+ O
79 O
relative O
to O
the O
most O
5 O
' O
of O
several O
discrete O
transcription O
start O
points O
. O

Structure O
of O
the O
EMAPII ALLCAPS
domain O
of O
human O
aminoacyl RARE
- O
tRNA O
synthetase I-GENE
complex I-GENE
reveals O
evolutionary O
dimer O
mimicry RARE
. O

Adding RARE
10 O
mmol O
SDS O
/ O
l O
led O
to O
transient O
inhibition O
of O
acidification O
, O
metal O
solubilization RARE
and O
sulfur O
oxidation O
. O

Competition O
electrophoretic O
mobility O
shift O
and O
immunoshift RARE
assays O
confirmed O
that O
NF1 I-GENE
factors I-GENE
present O
in O
nuclear O
extracts O
of O
HeLa O
and O
CV ALLCAPS
- O
1 O
cells O
bind O
to O
the O
BKV ALLCAPS
- O
MLP ALLCAPS
. O

Northern O
and O
Western O
blot O
analyses O
demonstrated O
that O
Graf2 NUMERIC
is O
expressed O
in O
several O
tissues O
, O
with O
the O
highest O
expression O
in O
skeletal O
muscle O
. O

A O
minimal O
ER3 NUMERIC
sequence O
of O
DNA O
was O
further O
demonstrated O
to O
function O
as O
a O
FXR ALLCAPS
HRE ALLCAPS
and O
was O
bound O
in O
vitro O
by O
FXR ALLCAPS
- O
expressing O
yeast O
extracts O
. O

In O
Ka13 NUMERIC
cells O
, O
CoCl RARE
( O
2 O
) O
stimulated O
expression O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
under O
the O
control O
of O
a O
15 O
- O
kilobase O
pair O
mouse O
ho RARE
- O
1 O
promoter O
( O
pHO15luc NUMERIC
). O

Nine RARE
strains O
were O
subtyped RARE
as O
Camp RARE
. O
jejuni RARE
subsp RARE
. O
jejuni RARE
biotype RARE
II I-GENE
and O
the O
remaining O
ones O
as O
biotype RARE
I O
. O

The O
Ig I-GENE
- I-GENE
related I-GENE
, O
typical O
metazoan RARE
, O
module RARE
is O
classified O
to O
the O
disulphide RARE
lacking O
Ig I-GENE
members I-GENE
and O
represents O
the O
phylogenetic O
earliest RARE
member O
of O
this O
group O
. O

In O
budding O
yeast O
, O
this O
latter O
checkpoint O
response O
involves O
the O
proteins O
Mad1 NUMERIC
, O
2 O
, O
3 O
, O
Bub1 NUMERIC
and O
Bub3 NUMERIC
, O
whose O
vertebrate O
counterparts O
localize O
to O
unattached RARE
kinetochores RARE
. O

We O
investigated O
the O
production O
of O
hyaluronan RARE
( O
HA ALLCAPS
) O
and O
its O
effect O
on O
cell O
motility O
in O
cells O
expressing O
the O
v O
- O
src I-GENE
mutants I-GENE
. O

Oral RARE
supplementation O
of O
L O
- O
arginine O
significantly O
increased O
plasma O
L O
- O
citrulline RARE
, O
which O
indicated O
enhancement O
of O
NO O
production O
. O

We O
can O
classify RARE
antibiotics O
into O
two O
groups O
based O
on O
initial O
bactericidal O
activity O
against O
P O
. O
aeruginosa O
; O
one O
class O
is O
antibiotics O
having O
rapid O
initial O
killing RARE
such O
as O
AMK ALLCAPS
, O
IPM ALLCAPS
and O
PAPM ALLCAPS
, O
the O
other O
is O
CAZ ALLCAPS
, O
MEPM ALLCAPS
showing O
slow O
initial O
killing RARE
. O

The O
presence O
of O
truncated O
receptor O
isoforms O
in O
diverse O
species O
suggests O
that O
these O
proteins O
may O
have O
important O
functional O
roles O
in O
regulating O
EGFR I-GENE
activity O
. O

Of O
its O
gene O
products O
, O
E6 I-GENE
binds O
to O
and O
inactivates RARE
p53 I-GENE
tumor I-GENE
suppressor I-GENE
protein I-GENE
by O
ubiquitin I-GENE
/ I-GENE
proteasome I-GENE
- I-GENE
dependent I-GENE
degradation O
. O

Low O
affinity O
binding O
of O
Rab6A NUMERIC
- O
GTP O
was O
also O
observed O
( O
K O
( O
d O
) O
= O
16 O
microm O
), O
whereas O
Rab1B NUMERIC
, O
- O
5 O
, O
- O
7 O
, O
- O
8 O
, O
or O
- O
11A NUMERIC
did O
not O
bind O
. O

( O
1997 O
) O
Nature RARE
387 NUMERIC
, O
370 NUMERIC
- O
376 NUMERIC
)], RARE
we O
suggest O
that O
the O
metal O
fluoride O
ions O
replaced O
phosphate O
at O
the O
two O
ATP O
- O
binding O
sites O
of O
the O
iron O
protein O
, O
Kp2 NUMERIC
. O

A O
1 O
- O
base O
pair O
mismatch RARE
within O
the O
corresponding O
region O
of O
the O
CYP3A4 NUMERIC
gene I-GENE
was O
sufficient O
for O
a O
differential O
enhancer O
activity O
. O

AIMS ALLCAPS
: O
To O
establish O
a O
baseline O
and O
intraindividual RARE
fluctuations O
of O
the O
tumour O
markers O
CEA ALLCAPS
, O
CA O
50 O
and O
CA O
242 NUMERIC
in O
patients O
cured RARE
from O
colorectal RARE
cancer O
, O
and O
to O
test O
the O
hypothesis O
that O
serum O
concentrations O
and O
intraindividual RARE
fluctuations O
do O
not O
differ O
from O
the O
concentrations O
in O
cancer O
- O
free O
individuals O
. O

Substitution O
of O
serine O
residues O
at O
the O
C O
- O
terminus O
indicated O
that O
loss O
of O
phosphorylation O
sites O
did O
not O
appear O
to O
have O
any O
effect O
on O
transcription O
and O
replication O
. O

Molecular O
analysis O
of O
the O
pRA2 NUMERIC
partitioning RARE
region O
: O
ParB RARE
autoregulates RARE
parAB RARE
transcription O
and O
forms O
a O
nucleoprotein RARE
complex O
with O
the O
plasmid O
partition RARE
site O
, O
parS LASTCAP
. O

Tumor RARE
cell O
lines O
transduced RARE
at O
an O
MOI ALLCAPS
of O
8 O
for O
3 O
days O
led O
to O
> O
90 O
% O
gene O
transfer O
efficiency O
. O

No O
ISREs RARE
could O
be O
identified O
in O
the O
mouse O
promoter O
. O

GABA ALLCAPS
( O
B O
) O
R1g NUMERIC
was O
expressed O
in O
both O
brain O
and O
peripheral O
tissues O
. O

Granulocyte RARE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
G I-GENE
- I-GENE
CSF I-GENE
) O
administration O
in O
vivo O
has O
been O
shown O
to O
improve O
the O
defence RARE
mechanisms O
against O
infection O
by O
different O
microbes RARE
. O

Use O
of O
a O
dual O
- O
pulse O
lithotripter RARE
to O
generate O
a O
localized O
and O
intensified RARE
cavitation RARE
field O
. O

The O
best O
regression O
model O
for O
predicting O
changes O
in O
the O
WCXR ALLCAPS
included O
time O
to O
first O
positive O
culture O
and O
antibody O
titer O
for O
Pa RARE
elastase I-GENE
. O

RESULTS O
: O
The O
parameters O
SF2 NUMERIC
and O
plating RARE
efficiency O
were O
stable O
throughout O
the O
4 O
- O
year O
test O
period O
. O

The O
process O
has O
been O
applied O
to O
the O
river RARE
reclamation RARE
in O
Yangpu RARE
District RARE
of O
Shanghai RARE
City O
, O
China RARE
. O

Multiple O
regression O
analysis O
performed O
between O
these O
long O
- O
term O
abiotic RARE
factors O
and O
nymphal RARE
abundance O
in O
positive O
sites O
showed O
high O
relationship O
( O
R2 O
coefficients O
) O
for O
every O
habitat RARE
category O
and O
explained O
> O
50 O
% O
of O
the O
variation O
in O
tick RARE
abundance O
. O

The O
v O
- O
Src I-GENE
SH3 I-GENE
domain I-GENE
facilitates RARE
a O
cell O
adhesion O
- O
independent O
association O
with O
focal O
adhesion O
kinase I-GENE
. O

Of O
the O
six O
cases O
of O
malignant O
polyposis RARE
, O
none O
were O
identified O
using O
CT O
, O
and O
only O
two O
were O
diagnosed O
by O
small O
bowel O
follow O
- O
through O
. O

Right RARE
LHR I-GENE
( O
R I-GENE
- I-GENE
LHR I-GENE
) O
provided O
the O
best O
interobserver RARE
and O
intraobserver RARE
reproducibility O
. O

We O
also O
reported O
the O
identification O
of O
three O
corresponding O
alternative O
first O
exons O
and O
an O
intronic O
promoter O
in O
the O
human O
PDE5A NUMERIC
gene I-GENE
. O

Of O
major O
concern RARE
to O
food O
processors RARE
is O
the O
inadvertent RARE
cross O
- O
contact O
of O
food O
products O
with O
allergenic RARE
residues O
, O
which O
could O
result O
in O
potentially O
life O
- O
threatening RARE
reactions O
in O
those O
with O
a O
food O
allergy O
. O

Diffuse RARE
myalgias RARE
were O
more O
frequent O
in O
patients O
with O
than O
without O
an O
MMF ALLCAPS
lesion O
at O
deltoid RARE
muscle O
biopsy O
( O
P O
< O
0 O
. O
0001 O
). O

Functional O
analysis O
of O
various O
PTP I-GENE
- I-GENE
deficient O
DT40 NUMERIC
B I-GENE
cell O
lines O
stably O
expressing O
wild O
- O
type O
chimeric O
Fc I-GENE
gamma I-GENE
RIIB1 NUMERIC
- I-GENE
PECAM ALLCAPS
- I-GENE
1 I-GENE
receptor I-GENE
indicated O
that O
cytoplasmic O
Src I-GENE
homology I-GENE
2 I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing O
phosphatases I-GENE
, O
SHP I-GENE
- I-GENE
1 I-GENE
and O
SHP I-GENE
- I-GENE
2 I-GENE
, O
were O
both O
necessary O
and O
sufficient O
to O
deliver RARE
inhibitory O
negative O
regulation O
upon O
coligation RARE
of O
BCR I-GENE
complex I-GENE
with O
inhibitory O
receptor O
. O

Subtraction RARE
hybridization O
identified O
melanoma O
differentiation O
associated O
gene O
- O
7 O
( O
mda RARE
- O
7 O
), O
as O
a O
gene O
induced O
during O
these O
physiological O
changes O
in O
human O
melanoma O
cells O
. O

A O
rare O
case O
of O
primary O
group O
A O
streptococcal RARE
peritonitis RARE
. O

Among O
individuals O
, O
however O
, O
changes O
were O
strongly O
correlated O
with O
ACR ALLCAPS
levels O
at O
baseline O
. O

RESULTS O
: O
The O
subjects O
in O
the O
augmented O
feedback RARE
group O
significantly O
reduced O
their O
peak O
vertical O
ground RARE
reaction O
force O
in O
both O
post O
- O
test O
conditions O
( O
2 O
- O
minute O
post O
- O
test O
reduction O
, O
0 O
. O
85 O
+/- O
0 O
. O
62 O
; O
1 O
- O
week O
post O
- O
test O
reduction O
, O
0 O
. O
74 O
+/- O
0 O
. O
58 O
) O
as O
compared O
to O
the O
sensory O
, O
control O
I O
, O
and O
control O
II O
feedback RARE
groups O
. O

The O
blood O
levels O
of O
lactate O
, O
pyruvate RARE
and O
amino O
acids O
were O
not O
elevated O
. O

Histological O
examination O
showed O
lichenoid RARE
changes O
, O
acantholytic RARE
blister RARE
formation O
and O
apoptotic O
keratinocytes RARE
. O

Enantiomer RARE
separation O
of O
venlafaxine RARE
and O
O O
- O
desmethylvenlafaxine RARE
in O
human O
plasma O
. O

Paul RARE
Monagle RARE
addresses RARE
the O
epidemiology RARE
of O
neonatal O
thrombosis O
outside O
of O
the O
central O
nervous O
system O
in O
both O
arterial O
and O
venous O
locations O
, O
and O
those O
that O
occur O
in O
utero RARE
. O

The O
MSL ALLCAPS
complex O
is O
specifically O
localized O
on O
the O
male O
X O
chromosome O
to O
increase O
its O
expression O
approximately O
2 O
- O
fold O
. O

Effects O
of O
a O
booster RARE
dose O
of O
tetanus RARE
toxoid RARE
after O
different O
primary O
courses O
of O
vaccination O
: O
implications O
on O
the O
use O
of O
immune O
globulin I-GENE
. O

Our O
results O
suggest O
that O
the O
C O
- O
terminal O
region O
of O
Crk I-GENE
contains O
negative O
regulatory O
elements O
important O
for O
both O
Abl I-GENE
and O
FAK I-GENE
dependent I-GENE
signal I-GENE
pathways O
, O
and O
offers O
a O
paradigm RARE
for O
an O
autoinhibitory RARE
region O
in O
the O
SH3 I-GENE
linker O
/ O
C O
- O
terminal O
SH3 I-GENE
domain I-GENE
. O

The O
distribution O
of O
red O
rice O
cultivation RARE
in O
Sri RARE
Lanka RARE
is O
coincident RARE
with O
the O
HIDD ALLCAPS
villages RARE
. O

Prophylactic RARE
lymph O
node O
dissection O
or O
radiation O
therapy O
to O
the O
nodal O
chain O
may O
decrease O
local O
recurrence O
but O
does O
not O
consistently O
affect O
overall O
survival O
. O

Secretion RARE
of O
interleukin I-GENE
- I-GENE
8 I-GENE
, O
RANTES ALLCAPS
, O
macrophage O
inflammatory O
protein O
1alpha I-GENE
, O
and O
10 O
- O
kappaDa RARE
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
inducible I-GENE
protein I-GENE
were O
increased O
in O
differentiating O
keratinocytes RARE
by O
E6 I-GENE
. O

CONCLUSIONS O
: O
ChromaFlo RARE
- O
enhanced O
IVUS ALLCAPS
demonstrates O
colorized RARE
blood O
flow O
inside RARE
the O
vessel O
lumen RARE
, O
which O
is O
helpful O
in O
distinguishing RARE
echolucent RARE
disease O
from O
luminal O
blood O
flow O
and O
can O
also O
be O
used O
to O
perform O
peripheral O
interventions RARE
in O
patients O
with O
renal O
failure O
or O
allergy O
, O
avoiding RARE
the O
use O
of O
contrast O
media O
. O

Additional RARE
factors O
such O
as O
advanced O
age O
, O
concomitant O
use O
of O
corticosteroids O
or O
anticoagulants RARE
, O
prior O
ulcer O
complications O
and O
co O
- O
morbid RARE
diseases O
may O
further O
increase O
the O
risk O
of O
bleeding O
. O

CONCLUSIONS O
: O
Using O
icodextrin RARE
- O
based O
instead O
of O
glucose O
- O
based O
PD ALLCAPS
fluids O
can O
largely O
reduce O
the O
formation O
of O
Amadori RARE
albumin I-GENE
and O
AGEs RARE
. O

A O
central O
finding O
is O
the O
identification O
of O
a O
GC O
- O
rich O
sequence O
in O
the O
- O
99 O
/- O
91 O
Cp I-GENE
region I-GENE
that O
is O
essential O
for O
oriPI RARE
- O
EBNA1 NUMERIC
- O
independent O
as O
well O
as O
oriPI RARE
- O
EBNA1 NUMERIC
- O
dependent O
activity O
of O
the O
promoter O
. O

Furthermore O
, O
SB203580 NUMERIC
inhibited O
LPS O
- O
induced O
activation O
of O
Sp1 I-GENE
, O
as O
well O
as O
the O
promoter O
activity O
in O
cells O
transfected O
with O
a O
plasmid O
containing O
the O
Sp1 I-GENE
consensus I-GENE
sequence I-GENE
. O

A O
new O
echocardiographic O
technique O
is O
described O
with O
a O
conventional O
M O
mode O
, O
digitalised RARE
2D NUMERIC
and O
tissular RARE
Doppler O
which O
has O
a O
comparable O
ability O
to O
identify O
the O
anomalous RARE
pathways O
of O
electric RARE
conduction O
using O
a O
non O
- O
invasive O
method O
. O

Is O
clopidogrel RARE
superior O
to O
aspirin O
in O
secondary O
prevention O
of O
vascular O
disease O
? O
The O
cornerstone RARE
in O
clinical O
evidence O
of O
the O
relative O
efficacy O
of O
thienopyridines RARE
( O
clopidogrel RARE
, O
ticlopidine RARE
) O
versus O
aspirin O
in O
the O
secondary O
prevention O
of O
vascular O
disease O
is O
the O
Clopidogrel RARE
versus O
Aspirin RARE
in O
Patients O
at O
Risk O
of O
Ischaemic RARE
Events RARE
trial O
. O

The O
role O
of O
the O
Vp1 NUMERIC
DBD ALLCAPS
during O
infection O
was O
investigated O
by O
taking O
advantage O
of O
NLS O
phenotypic RARE
complementation O
( O
N O
. O

The O
probability RARE
of O
treatment O
with O
lamotrigine RARE
being O
maintained O
for O
six O
months O
was O
86 O
%, O
for O
twelve RARE
months O
61 O
% O
and O
for O
three O
years O
31 O
%. O

Recent O
advances RARE
have O
shown O
that O
volatile O
sulfur O
is O
a O
result O
of O
ecological RARE
interactions O
and O
transformation O
processes O
through O
planktonic RARE
food O
webs RARE
. O

OsBBPI RARE
was O
found O
to O
be O
rapidly O
induced O
in O
rice O
seedling RARE
leaf O
in O
response O
to O
cut O
, O
exogenous O
jasmonic RARE
acid O
( O
JA ALLCAPS
), O
and O
two O
potent O
protein O
phosphatase I-GENE
2A I-GENE
( O
PP2A I-GENE
) I-GENE
inhibitors O
, O
cantharidin RARE
( O
CN ALLCAPS
) O
and O
endothall RARE
( O
EN ALLCAPS
), O
in O
a O
light O
/ O
dark O
-, O
time O
- O
and O
dose O
- O
dependent O
manner O
; O
this O
induction O
was O
completely O
inhibited O
by O
cycloheximide RARE
( O
CHX ALLCAPS
), O
indicating O
a O
requirement O
for O
de O
novo O
protein O
synthesis O
in O
its O
induction O
. O

Analysis O
of O
ace2Delta NUMERIC
cells O
reveals O
that O
Ace2p NUMERIC
is O
required O
for O
cell O
separation O
but O
not O
for O
polarized RARE
growth O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
study O
the O
morphological O
characteristics O
of O
the O
fibrous RARE
tissue O
capsule RARE
resulting O
from O
the O
implantation O
of O
aluminum O
calcium O
phosphate O
( O
ALCAP ALLCAPS
) O
and O
hydroxyapetite RARE
( O
HA ALLCAPS
) O
bioceramics RARE
. O

The O
event O
rate O
in O
patients O
with O
chronic O
Irr RARE
- O
rMFP RARE
or O
Un RARE
- O
nrMFP RARE
was O
markedly O
higher O
than O
it O
was O
in O
those O
with O
Rev I-GENE
- I-GENE
rMFP RARE
or O
Sta RARE
- O
nrMFP RARE
. O

In O
summary O
, O
we O
conclude O
that O
the O
adenoviral RARE
oncoprotein RARE
E1A I-GENE
activates O
transcription O
from O
the O
endogenous O
AP I-GENE
- I-GENE
2alpha I-GENE
gene I-GENE
, O
an O
effect O
that O
involves O
transcriptional O
derepression O
of O
the O
AP I-GENE
- I-GENE
2alpha I-GENE
promoter I-GENE
by O
interaction O
of O
E1A I-GENE
with O
the O
AP I-GENE
- I-GENE
2rep NUMERIC
corepressor RARE
CtBP1 NUMERIC
. O

Unusual RARE
two O
- O
domain O
arginine O
kinases I-GENE
( O
AKs RARE
) O
arose RARE
independently O
at O
least O
two O
times O
during O
molecular O
evolution O
of O
phosphagen RARE
kinases I-GENE
: O
AKs RARE
from O
the O
primitive RARE
sea O
anemone RARE
Anthopleurura RARE
japonicus RARE
and O
from O
the O
clam RARE
Pseudocardium RARE
sachalinensis RARE
. O

Mutagenesis RARE
of O
SNT1 NUMERIC
( O
IRS I-GENE
) I-GENE
CX ALLCAPS
identified O
three O
classes O
of O
effector O
motifs O
within O
SNT ALLCAPS
critical O
for O
both O
sustained O
ERK I-GENE
activation O
and O
neuronal O
differentiation O
: O
1 O
) O
four O
phosphotyrosine O
motifs O
that O
mediate O
recruitment O
of O
Grb2 I-GENE
, O
2 O
) O
two O
phosphotyrosine O
motifs O
that O
mediate O
recruitment O
of O
Shp2 NUMERIC
, O
and O
3 O
) O
a O
C O
- O
terminal O
motif O
that O
functions O
by O
helping RARE
to O
recruit O
Sos I-GENE
. O

CONCLUSIONS O
: O
Our O
meta RARE
- O
analysis O
of O
randomized O
controlled O
trials O
of O
HRT ALLCAPS
noted O
a O
statistically O
significant O
reduction O
in O
nonvertebral RARE
fractures RARE
. O

However O
, O
C4B NUMERIC
proteins I-GENE
encoded O
by O
monomodular RARE
short O
genes O
may O
have O
relatively O
higher O
concentrations O
than O
those O
from O
long O
C4A NUMERIC
genes I-GENE
. O

CSR ALLCAPS
is O
directed O
to O
specific O
heavy O
chain O
isotypes RARE
by O
cytokines O
and O
B O
cell O
activators O
that O
induce O
transcription O
from O
the O
unrearranged RARE
, O
or O
germline O
( O
GL ALLCAPS
), O
C O
( O
H O
) O
region O
genes O
. O

The O
patterns O
of O
early O
mRNA O
and O
protein O
expression O
in O
these O
seven O
mutants O
were O
examined O
, O
and O
it O
was O
found O
that O
mutation O
of O
the O
T O
'( RARE
135 O
) O
acceptor O
site O
resulted O
in O
the O
utilization O
of O
cryptic RARE
splice O
sites O
and O
the O
generation O
of O
new O
T O
' O
species O
. O

Mutational O
analysis O
showed O
that O
the O
U O
- O
box O
, O
like O
the O
RING ALLCAPS
finger I-GENE
in O
other O
proteins O
, O
forms O
the O
physical O
basis O
for O
the O
interaction O
with O
E2 O
enzymes O
. O

GafChromic RARE
( O
MD ALLCAPS
- O
55 O
- O
2 O
) O
radiochromic RARE
film RARE
has O
become O
increasingly RARE
popular RARE
for O
medical O
applications O
and O
has O
proven O
to O
be O
useful O
for O
brachytherapy RARE
dosimetry RARE
. O

The O
438 NUMERIC
bp O
EcoRI I-GENE
fragment I-GENE
, O
which O
was O
detected O
by O
Southern O
hybridization O
, O
reveals O
an O
open O
reading O
frame O
which O
encodes O
a O
protein O
of O
103 NUMERIC
amino O
acids O
. O

Furthermore O
, O
hormonal O
regulation O
of O
G O
( O
1 O
) O
gene O
transcription O
can O
occur O
even O
without O
additional O
activation O
of O
the O
Mek RARE
- O
Erk1 NUMERIC
/ O
2 O
pathway O
by O
estrogen O
receptors O
. O

In O
mammalian O
tissue O
culture O
cells O
, O
overexpression O
of O
any O
of O
the O
four O
mouse O
deltex RARE
homologs O
suppressed O
the O
transcriptional O
activity O
of O
E47 NUMERIC
, O
a O
basic O
helix O
- O
loop O
- O
helix O
( O
bHLH O
) O
protein O
, O
in O
a O
manner O
similar O
to O
suppression O
by O
an O
activated O
form O
of O
human O
Notch1 NUMERIC
or O
human O
DTX1 NUMERIC
. O

The O
authors O
undertook RARE
a O
retrospective O
analysis O
of O
pathology O
with O
quantification RARE
of O
the O
percentage O
of O
papillary RARE
serous RARE
component O
(% RARE
PSC ALLCAPS
) O
and O
p53 I-GENE
expression O
. O

This O
function O
requires O
not O
only O
the O
kinase I-GENE
domain I-GENE
of O
Csk I-GENE
, O
but O
also O
its O
Src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
) I-GENE
and O
SH2 I-GENE
regions I-GENE
. O

Nucleotide O
sequence O
, O
transcription O
map O
, O
and O
mutation O
analysis O
of O
the O
13q14 NUMERIC
chromosomal O
region O
deleted O
in O
B O
- O
cell O
chronic O
lymphocytic RARE
leukemia O
. O

In O
conclusion O
, O
primary O
chemotherapy O
based O
on O
high O
dose O
MTX ALLCAPS
and O
ara RARE
- O
C O
is O
highly O
efficient O
in O
PCNSL ALLCAPS
. O

NGF ALLCAPS
, O
but O
not O
EGF I-GENE
, O
enhances O
the O
upper O
bands O
, O
corresponding O
to O
phosphorylated O
Fra RARE
- O
2 O
. O

METHODS O
AND O
RESULTS O
: O
Palmaz RARE
- O
Schatz RARE
stents RARE
were O
dip RARE
- O
coated RARE
with O
paclitaxel RARE
( O
0 O
, O
0 O
. O
2 O
, O
15 O
, O
or O
187 NUMERIC
microgram O
/ O
stent RARE
) O
by O
immersion O
in O
ethanolic RARE
paclitaxel RARE
and O
evaporation RARE
of O
the O
solvent O
. O

Currently RARE
, O
the O
clinical O
use O
of O
5 O
- O
aminolaevulinic RARE
acid O
( O
ALA ALLCAPS
) O
induced O
protoporphyrin RARE
IX I-GENE
( O
PPIX ALLCAPS
) O
for O
photodynamic RARE
therapy O
( O
PDT ALLCAPS
) O
is O
limited O
by O
the O
maximum O
tolerated O
oral O
ALA ALLCAPS
dose O
( O
60 O
mg O
/ O
kg O
). O

A O
twelfth RARE
insertion O
disrupts RARE
two O
genes O
, O
Nrk RARE
, O
a O
" O
neurospecific RARE
" O
receptor O
tyrosine O
kinase I-GENE
, O
and O
Tpp RARE
, O
which O
encodes O
a O
neuropeptidase RARE
. O

These O
results O
indicate O
that O
ATF4 NUMERIC
regulates O
basal O
and O
CdCl RARE
( O
2 O
)- O
induced O
expression O
of O
the O
ho RARE
- O
1 O
gene O
in O
a O
cell O
- O
specific O
manner O
and O
possibly O
in O
a O
complex O
with O
Nrf2 NUMERIC
. O

Adjuvant RARE
and O
neoadjuvant RARE
treatment O
of O
breast O
cancer O
. O

The O
% O
SVend RARE
of O
HCM ALLCAPS
- O
I O
was O
significantly O
lower O
than O
the O
respective O
values O
of O
the O
HCM ALLCAPS
- O
II O
and O
Control O
groups O
. O

Inhibition O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
target I-GENE
ERK I-GENE
kinase I-GENE
( O
MEK I-GENE
) I-GENE
either O
attenuated O
or O
abolished O
Rp RARE
- O
cAMPS RARE
- O
and O
PKI ALLCAPS
- O
induced O
ERK I-GENE
activation O
, O
caldesmon RARE
phosphorylation O
, O
and O
stress O
fiber O
formation O
. O

In O
the O
TVD ALLCAPS
- O
patients O
decreases O
in O
skin O
blood O
flow O
were O
similar O
compared O
with O
the O
healthy O
controls O
. O

Analysis O
of O
mCTR RARE
mRNAs O
has O
revealed O
that O
the O
three O
alternative O
promoters O
give O
rise O
to O
at O
least O
seven O
mCTR RARE
isoforms O
in O
the O
5 O
' O
region O
of O
the O
gene O
and O
generate O
5 O
'- O
untranslated O
regions O
of O
very O
different O
lengths O
. O

The O
regulation O
of O
PGHS ALLCAPS
- O
2 O
mRNA O
and O
protein O
was O
studied O
in O
primary O
cultures O
of O
bovine O
uterine O
stromal RARE
cells O
stimulated O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
; O
100 O
nM O
). O

There O
was O
no O
evidence O
of O
linkage O
disequilibrium RARE
between O
the O
polymorphic O
site O
in O
the O
B O
cell O
specific O
promoter O
and O
those O
in O
the O
3 O
' O
UTR O
. O

Several O
dozen RARE
HIF I-GENE
- I-GENE
1 I-GENE
targets O
are O
known O
, O
including O
the O
gene O
encoding O
vascular O
endothelial O
growth O
factor O
( O
VEGF I-GENE
). O

In O
Klinefelter RARE
' O
s O
syndrome O
( O
47XXY NUMERIC
), O
serum O
testosterone O
levels O
are O
at O
the O
lower O
end O
of O
the O
normal O
range O
and O
dihydrotestosterone RARE
levels O
are O
low O
. O

The O
protein O
is O
composed O
of O
two O
major O
domains O
separated O
by O
a O
hydrophobic O
linker O
region O
of O
20 O
amino O
acid O
residues O
. O

When O
mixed O
with O
aqueous O
solutions O
of O
TMT ALLCAPS
- O
55 O
, O
aqueous O
solutions O
of O
either O
reagent RARE
- O
grade O
zinc O
, O
cadmium O
, O
or O
lead O
salts RARE
precipitate RARE
crystalline O
" O
Zn O
- O
TMT ALLCAPS
", RARE
amorphous RARE
or O
crystalline O
" O
Cd O
- O
TMT ALLCAPS
" O
or O
amorphous RARE
" O
Pb RARE
- O
TMT ALLCAPS
" O
( O
M3 NUMERIC
[ O
S3C3N3 NUMERIC
] O
2 O
. O
nH2O NUMERIC
, O
where O
M O
= O
Cd2 NUMERIC
+, O
Pb2 NUMERIC
+, O
and O
Zn2 NUMERIC
+ O
and O
n O
> O
or O
= O
0 O
) O
that O
may O
eventually RARE
crystallize RARE
if O
stored O
in O
air O
. O

Online RARE
teaching RARE
: O
design O
and O
techniques O
. O

This O
interaction O
is O
reciprocal O
, O
since O
C O
/ O
EBP I-GENE
dimer O
binding O
to O
a O
strong O
C O
/ O
EBP I-GENE
site I-GENE
leads O
to O
enhanced O
CREB I-GENE
- I-GENE
1 I-GENE
recruitment O
to O
ATF I-GENE
/ I-GENE
CREB I-GENE
sites I-GENE
that O
are O
weakly O
bound O
by O
CREB I-GENE
. O

The O
absorbed O
dose O
was O
measured O
by O
combination O
of O
two O
integrating RARE
detectors RARE
: O
thermo RARE
- O
luminescent RARE
dosemeter RARE
of O
Mg2SiO4 NUMERIC
: O
Tb RARE
( O
TDMS ALLCAPS
) O
and O
plastic RARE
nuclear O
track RARE
detector O
( O
PNTD ALLCAPS
). O

To O
determine O
the O
genomic O
complexity O
of O
the O
deleted O
region O
shared O
among O
tumors O
, O
we O
assembled O
a O
physical O
map O
of O
the O
I O
Mbp RARE
SRO ALLCAPS
consisting O
predominantly O
of O
bacteriophage O
P1 O
- O
derived O
artificial O
chromosome O
( O
PAC ALLCAPS
) O
clones O
. O

Thus O
, O
Xlim RARE
- O
1 O
not O
only O
contains O
a O
unique O
tyrosine O
- O
rich O
activation O
domain O
but O
also O
contains O
a O
negative O
regulatory O
domain O
in O
CT239 NUMERIC
- O
403 NUMERIC
, O
suggesting O
a O
complex O
regulatory O
mechanism O
underlying O
the O
transcriptional O
activity O
of O
Xlim RARE
- O
1 O
in O
the O
organizer RARE
. O

Low O
- O
selenium O
diet O
has O
a O
human O
unfavourable RARE
impact O
. O

In O
the O
next O
week O
, O
the O
beta O
- O
adrenergic O
antagonist O
atenolol RARE
was O
added O
at O
an O
initial O
dose O
of O
25 O
mg O
/ O
day O
and O
titrated RARE
to O
50 O
mg O
/ O
day O
within O
1 O
week O
. O

To O
assess O
more O
specific O
PKA I-GENE
- I-GENE
dependent I-GENE
mediation RARE
of O
LH I-GENE
' I-GENE
s O
contribution O
to O
combined O
hormonal O
drive O
, O
the O
LDL I-GENE
receptor I-GENE
(- O
1076 NUMERIC
to O
+ O
11 O
bp O
) O
reporter O
plasmid O
was O
cotransfected O
with O
a O
full O
- O
sequence O
rabbit O
muscle O
protein O
kinase I-GENE
inhibitor I-GENE
( O
PKI ALLCAPS
) O
minigene RARE
driven O
constitutively O
by O
a O
Rous RARE
sarcoma O
virus O
promoter O
. O

In O
SN ALLCAPS
- O
48 O
neuronal O
cells O
that O
express O
MR O
, O
GR I-GENE
, O
and O
5 O
- O
HT1A NUMERIC
receptors I-GENE
, O
deletion O
or O
inactivation O
of O
the O
nGRE RARE
( O
negative O
GRE O
) O
eliminated RARE
negative O
regulation O
of O
the O
rat O
5 O
- O
HT1A NUMERIC
or O
heterologous O
promoters O
by O
corticosteroids O
, O
whereas O
its O
inclusion O
conferred O
corticosteroid O
- O
induced O
inhibition O
to O
a O
heterologous O
promoter O
. O

Transition RARE
between O
P O
- O
and O
H O
- O
BPPV ALLCAPS
was O
found O
in O
6 O
cases O
. O

These O
included O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
, O
HFH ALLCAPS
- O
1 O
, O
HFH ALLCAPS
- O
2 O
, O
HFH ALLCAPS
- O
3 O
, O
C O
/ O
EBP I-GENE
, O
and O
C O
/ O
EBP I-GENE
beta I-GENE
, O
all O
of O
which O
are O
consistent O
with O
the O
tissue O
- O
specific O
expression O
profiles O
of O
the O
gene O
. O

RESULTS O
: O
Of O
the O
24 O
patients O
, O
6 O
had O
Grade RARE
1 O
pneumonitis RARE
, O
and O
13 O
had O
Grade RARE
2 O
pneumonitis RARE
. O

METHODS O
: O
The O
passive O
and O
active O
transport O
of O
fluorescein RARE
through O
the O
BRB ALLCAPS
was O
quantitated RARE
by O
vitreous O
fluorometry RARE
. O

Sixteen RARE
out O
of O
52 O
seropositive O
MS O
patients O
( O
30 O
. O
8 O
%) O
showed O
intrathecal RARE
synthesis O
of O
C O
. O
pneumoniae O
- O
specific O
IgG I-GENE
but O
only O
one O
of O
43 O
seropositive O
controls O
( O
2 O
. O
3 O
%). O

Consistent O
with O
the O
specificity O
observed O
for O
the O
interaction O
of O
DmCKIIalpha RARE
with O
these O
bHLH O
proteins O
, O
sequence O
alignment O
suggests O
that O
only O
m5 NUMERIC
, O
m7 NUMERIC
, O
and O
m8 NUMERIC
contain O
a O
consensus O
site O
for O
phosphorylation O
by O
CKII ALLCAPS
within O
a O
subdomain RARE
unique O
to O
these O
three O
proteins O
. O

Deletion O
of O
the O
potential O
initiator O
element O
does O
not O
affect O
repression O
of O
the O
p21 I-GENE
promoter I-GENE
by O
c I-GENE
- I-GENE
Myc I-GENE
. O

PATIENTS O
AND O
METHODS O
: O
Between RARE
June RARE
1991 O
and O
December RARE
1996 O
, O
we O
administered O
the O
nucleoside RARE
analog O
2 O
- O
chlorodeoxyadenosine RARE
( O
2 O
- O
CDA ALLCAPS
) O
to O
73 O
children O
with O
primary O
AML ALLCAPS
and O
20 O
children O
with O
secondary O
AML ALLCAPS
or O
myelodysplastic RARE
syndrome O
( O
MDS ALLCAPS
). O

Drosophila O
Menin1 NUMERIC
gene I-GENE
transcripts I-GENE
use O
alternative O
polyadenylation O
sites O
resulting O
in O
4 O
. O
3 O
and O
5 O
- O
kb O
messages RARE
. O

Mice RARE
homozygous O
for O
the O
dlg RARE
mutation O
exhibit O
growth O
retardation O
in O
utero RARE
, O
have O
hypoplasia RARE
of O
the O
premaxilla RARE
and O
mandible RARE
, O
have O
a O
cleft RARE
secondary O
palate RARE
, O
and O
die RARE
perinatally RARE
. O

In O
contrast O
, O
we O
did O
not O
detect O
a O
significant O
correlation O
between O
plasma O
TNFalpha RARE
and O
radiation O
pneumonitis RARE
. O

Its O
transcription O
in O
vitro O
by O
pol I-GENE
III I-GENE
requires O
the O
same O
factors O
as O
the O
U6 I-GENE
gene I-GENE
with O
the O
major O
exception O
that O
the O
modified O
TATA O
- O
box O
of O
this O
construct O
only O
interacts O
with O
a O
TATA O
- O
binding O
protein O
( O
TBP I-GENE
) I-GENE
mutant I-GENE
( O
TBP I-GENE
- I-GENE
DR2 NUMERIC
) O
but O
not O
with O
TBP I-GENE
wild I-GENE
- I-GENE
type I-GENE
( O
TBPwt RARE
). O

Expression O
of O
the O
src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
)- I-GENE
encoding I-GENE
, O
expressed O
in O
tumorigenic O
astrocytes RARE
( O
SETA ALLCAPS
) O
gene O
is O
associated O
with O
astrocyte RARE
transformation O
in O
culture O
and O
tumors O
in O
the O
adult O
brain O
. O

In O
such O
conditions O
, O
the O
following O
kinetic O
reactions O
have O
been O
studied O
: O
N2 O
( O
A O
) O
+ O
N2 O
( O
A O
) O
--> O
N2 O
( O
C O
, O
B O
, O
V O
') O
+ O
N2 O
( O
X O
), O
N2 O
( O
A O
) O
+ O
N2 O
( O
X O
, O
V O
> O
5 O
) O
--> O
N2 O
( O
X O
) O
+ O
N2 O
( O
B O
, O
V O
') O
in O
pure O
N2 O
post O
- O
discharges RARE
and O
N2 O
( O
A O
) O
+ O
CH4 NUMERIC
--> O
products O
, O
C O
+ O
N O
+ O
M2 NUMERIC
--> O
CN ALLCAPS
( O
B O
, O
V O
') O
+ O
M2 NUMERIC
, O
N2 O
( O
X O
, O
V O
> O
4 O
) O
+ O
CN ALLCAPS
--> O
N2 NUMERIC
( RARE
X ALLCAPS
) RARE
+ RARE
CN ALLCAPS
( RARE
B ALLCAPS
, RARE
A ALLCAPS
, RARE
V ALLCAPS
'), RARE
in RARE
N2 NUMERIC
- RARE
1 NUMERIC
% RARE
CH4 NUMERIC
post RARE
- RARE
discharges RARE
. RARE

BACKGROUND O
/ O
AIMS ALLCAPS
: O
Hepatitis O
C O
and O
nonalcoholic RARE
fatty O
liver O
disease O
( O
NAFL ALLCAPS
) O
are O
the O
two O
most O
common O
forms O
of O
liver O
disease O
in O
the O
United O
States RARE
. O

These O
results O
suggested O
a O
critical O
role O
for O
tyrosine O
residue O
1229 NUMERIC
in O
the O
regulation O
of O
L1 O
endocytosis RARE
. O

The O
androgen O
receptor O
( O
AR ALLCAPS
) O
amino O
- O
terminus O
imposes RARE
androgen O
- O
specific O
regulation O
of O
AR ALLCAPS
gene I-GENE
expression O
via O
an O
exonic RARE
enhancer O
. O

Can RARE
survival O
be O
prolonged O
for O
patients O
with O
hormone O
- O
resistant O
prostate O
cancer O
? O

In O
conclusion O
, O
NF I-GENE
- I-GENE
Y I-GENE
and O
Sp1 I-GENE
binding I-GENE
sites I-GENE
play O
a O
decisive RARE
role O
in O
the O
basal O
expression O
of O
the O
rat O
mrp2 NUMERIC
gene I-GENE
, O
while O
the O
human O
MRP2 NUMERIC
gene I-GENE
is O
regulated O
differently O
. O

Intact RARE
Flag RARE
- O
tagged O
protein O
products O
from O
all O
six O
were O
produced O
from O
genomic O
expression O
vectors O
, O
although O
the O
ORF40 NUMERIC
/ O
41 NUMERIC
transcript O
encoding O
a O
primase I-GENE
- I-GENE
helicase I-GENE
component O
proved O
to O
be O
spliced O
with O
a O
127 NUMERIC
- O
bp O
intron O
. O

Hypomorphic RARE
dSLBP RARE
alleles O
support O
zygotic RARE
development O
but O
cause O
female O
sterility RARE
. O

In O
hypertensive O
nephrosclerosis RARE
, O
therapy O
containing O
an O
ACEI ALLCAPS
alone O
or O
in O
combination O
significantly O
reduces O
the O
incidence O
of O
renal O
events O
. O

We O
confirmed O
the O
interaction O
between O
TLS ALLCAPS
and O
p65 I-GENE
by O
the O
pull RARE
- O
down O
assay O
in O
vitro O
and O
by O
a O
coimmunoprecipitation RARE
experiment O
followed O
by O
Western O
blot O
of O
the O
cultured O
cell O
in O
vivo O
. O

In O
addition O
, O
we O
did O
not O
detect O
significant O
differences O
in O
CDR3 NUMERIC
sequences O
of O
endogenous O
Ig I-GENE
lambdaL LASTCAP
and O
kappaL LASTCAP
chain I-GENE
gene I-GENE
loci I-GENE
cloned O
from O
peripheral O
blood O
lymphocytes O
of O
an O
NBS ALLCAPS
patient O
and O
of O
healthy O
individuals O
. O

The O
diet O
of O
migrants RARE
showed O
both O
positive O
( O
macronutrients RARE
) O
and O
negative O
( O
micronutrients RARE
) O
differences O
with O
the O
general O
Dutch RARE
diet O
. O

Copyright O
2001 NUMERIC
Academic O
Press O
. O

Experimental O
study O
of O
ta RARE
chengchi RARE
tang RARE
decoction RARE
for O
relieving RARE
lung O
injury O
during O
acute O
necrotizing RARE
pancreatitis O
] O
The O
objectives RARE
of O
the O
study O
were O
to O
investigate O
the O
changes O
of O
leukocyte O
adhesiveness RARE
and O
tumor O
necrosis O
factor O
( O
TNF I-GENE
) I-GENE
in O
the O
early O
stage O
of O
acute O
necrotizing RARE
pancreatitis O
( O
ANP I-GENE
), O
to O
go RARE
further O
into O
the O
relation O
of O
those O
changes O
to O
lung O
injury O
of O
ANP I-GENE
, O
and O
to O
evaluate O
the O
prohibitive RARE
effect O
of O
ta RARE
chengchi RARE
tang RARE
Decoction RARE
on O
leukocyte O
adhesion O
and O
TNF I-GENE
secretion O
. O

We O
suggest O
that O
ventriculopleural RARE
shunting RARE
should O
be O
considered O
as O
the O
preferred O
alternative O
to O
peritoneal O
drainage O
in O
children O
with O
intra O
- O
abdominal O
adhesions O
or O
with O
a O
history O
of O
recent O
peritoneal O
infection O
. O

Positive RARE
and O
significant O
correlations O
were O
found O
between O
the O
weeks O
of O
pregnancy O
and O
Se RARE
levels O
in O
kidney O
( O
r O
= O
0 O
. O
433 NUMERIC
, O
P O
= O
0 O
. O
023 NUMERIC
) O
and O
heart O
( O
r O
= O
0 O
. O
313 NUMERIC
, O
P O
= O
0 O
. O
030 NUMERIC
). O

Doxorubicin RARE
( O
DOX ALLCAPS
) O
is O
commonly O
used O
for O
the O
treatment O
of O
hematological RARE
and O
solid O
tumors O
. O

There O
was O
no O
significant O
difference O
in O
developmental O
scores O
at O
9 O
or O
18 O
months O
, O
although O
PDF ALLCAPS
infants O
had O
a O
2 O
. O
8 O
(- O
1 O
. O
3 O
- O
6 O
. O
8 O
) O
point O
advantage O
in O
Bayley RARE
motor O
score O
scales RARE
. O

Immunofixation RARE
experiments O
of O
C4A NUMERIC
and O
C4B NUMERIC
demonstrate O
> O
41 O
allotypes RARE
in O
the O
two O
classes O
of O
proteins O
. O

These O
effects O
were O
not O
seen O
with O
SHIP2 NUMERIC
possessing RARE
a O
mutation O
in O
the O
SH2 I-GENE
domain I-GENE
( O
R47G NUMERIC
). O

Myasthenia RARE
gravis RARE
is O
an O
autoimmune RARE
disease O
resulting O
from O
the O
production O
of O
antibodies O
against O
the O
ACh RARE
receptors I-GENE
of O
the O
neuromuscular O
synapse RARE
. O

Human O
homologue O
of O
yeast O
Rad23 NUMERIC
protein I-GENE
A I-GENE
interacts O
with O
p300 I-GENE
/ I-GENE
cyclic I-GENE
AMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
( O
CREB I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
to O
down O
- O
regulate O
transcriptional O
activity O
of O
p53 I-GENE
. O

METHODS O
: O
Sixteen RARE
pigs O
were O
assigned O
randomly O
to O
control O
and O
shock O
groups O
. O

RESULTS O
: O
There O
is O
a O
considerable O
amount O
of O
variation O
between O
the O
results O
of O
TRA1 NUMERIC
and O
TRA2 NUMERIC
and O
between O
the O
results O
of O
both O
TRA ALLCAPS
' O
s O
and O
the O
door RARE
- O
to O
- O
door RARE
survey O
. O

Thus O
, O
our O
studies O
define O
Rac I-GENE
/ I-GENE
Cdc42 I-GENE
/ I-GENE
Pak RARE
as O
a O
module RARE
upstream O
of O
Raf I-GENE
- I-GENE
1 I-GENE
during O
its O
activation O
by O
microtubule O
disruption O
. O

Zhu RARE
, O
V O
. O

However O
, O
plasmids O
carrying O
the O
yeast O
TyrRS RARE
gene I-GENE
could O
not O
be O
stably O
maintained O
in O
E O
. O
coli O
. O

This O
supports O
previous O
arguments RARE
for O
the O
improbability RARE
of O
biological O
effects O
at O
UHF ALLCAPS
frequencies O
unless O
a O
mechanism O
can O
be O
found O
for O
accumulating RARE
energy O
over O
time O
and O
space O
and O
focussing RARE
it O
. O

The O
students O
who O
had O
abnormal O
urine O
screening O
results O
at O
the O
first O
time O
received O
a O
second O
urine O
analysis O
10 O
to O
15 O
days O
later O
to O
confirm O
the O
abnormal O
urine O
analysis O
. O

Cells RARE
containing O
alpha O
subunits O
that O
lacked O
a O
distal O
domain O
( O
term O
- O
3 O
) O
or O
had O
the O
alternatively O
spliced O
alpha I-GENE
- I-GENE
2 I-GENE
distal O
domain O
showed O
markedly O
decreased O
ability O
to O
support O
tyrosine O
phosphorylation O
of O
Jak I-GENE
- I-GENE
2 I-GENE
and O
its O
substrates O
or O
to O
up O
- O
regulate O
CD86 NUMERIC
. O

Despite O
abundant O
expression O
of O
NtmybAS RARE
transcripts O
in O
mature O
pollen O
, O
gPAL1 NUMERIC
transcripts I-GENE
were O
not O
detectable O
in O
pollen O
. O

Finally O
, O
profiling RARE
of O
a O
gcn4Delta NUMERIC
mutant I-GENE
uncovered RARE
an O
alternative O
induction O
pathway O
operating O
at O
many O
Gcn4p NUMERIC
target O
genes O
in O
histidine O
- O
starved RARE
cells O
. O

The O
R2 O
between O
MFI ALLCAPS
of O
fresh O
and O
frozen RARE
muscle O
was O
0 O
. O
94 O
and O
0 O
. O
92 O
for O
lamb RARE
and O
pork RARE
longissimus RARE
, O
respectively O
. O

To O
this O
end O
, O
an O
expression O
cassette O
consisting O
of O
the O
gene O
for O
a O
green O
fluorescent O
protein O
( O
GFP ALLCAPS
) O
flanked O
at O
its O
3 O
' O
end O
by O
EAV ALLCAPS
- O
specific O
transcription O
- O
regulating O
sequences O
was O
constructed O
. O

Significantly O
higher O
lung O
function O
parameters O
were O
obtained O
in O
extubated RARE
recipients O
of O
LPD ALLCAPS
preserved RARE
grafts O
2 O
weeks O
after O
TX ALLCAPS
. O

Lack RARE
of O
association O
between O
Kawasaki RARE
syndrome O
and O
infection O
with O
Rickettsia RARE
conorii RARE
, O
Rickettsia RARE
typhi RARE
, O
Coxiella RARE
burnetii RARE
or O
Ehrlichia RARE
phagocytophila RARE
group O
. O

These O
utilisation RARE
data O
imply O
annual O
drug O
costs O
in O
the O
range O
of O
$ RARE
US O
480 NUMERIC
, O
000 O
to O
$ RARE
US O
3 O
, O
600 O
, O
000 O
for O
TNF I-GENE
antagonists O
for O
RA O
per O
1 O
million O
population O
. O

Alignment RARE
of O
different O
cDNAs O
of O
the O
NR5A2 NUMERIC
( O
hB1F NUMERIC
) O
gene O
with O
the O
genomic O
sequence O
facilitated O
the O
delineation RARE
of O
its O
structural O
organization O
, O
which O
spans O
over O
150 O
kb O
and O
consists O
of O
eight O
exons O
interrupted O
by O
seven O
introns O
. O

CONCLUSIONS O
: O
Ketamine RARE
- O
induced O
dissociative RARE
anesthesia O
produces O
persistently RARE
elevated O
BIS ALLCAPS
index O
which O
is O
different O
from O
thiamylal RARE
and O
those O
reported O
with O
other O
conventional O
anesthetic RARE
agents O
. O

In O
the O
remaining O
case O
, O
the O
aneurysm RARE
originated RARE
from O
the O
proximal O
end O
of O
the O
associated O
A1 I-GENE
fenestration RARE
. O

This O
domain O
without O
the O
canonical O
anticodon RARE
loop O
or O
the O
tyrosine O
anticodon RARE
acts O
as O
an O
anchor O
for O
TyrRS RARE
interaction O
leading O
to O
a O
better O
efficiency O
of O
tyrosylation RARE
. O

Temperature RARE
measurement O
in O
microfluidic RARE
systems O
using O
a O
temperature O
- O
dependent O
fluorescent O
dye O
. O

The O
first O
exon O
( O
exon O
1A NUMERIC
) O
that O
corresponded O
to O
the O
5 O
'- O
untranslated O
region O
of O
the O
GHR ALLCAPS
1A NUMERIC
mRNA O
was O
15 O
, O
250 O
bp O
upstream O
from O
exon O
2 O
in O
the O
GHR ALLCAPS
gene I-GENE
. O

The O
NAUSICAA ALLCAPS
system O
gives O
a O
good O
knowledge O
of O
LET ALLCAPS
spectra O
for O
the O
first O
time O
in O
space O
dosimetry RARE
. O

The O
MABP ALLCAPS
and O
MCBFV ALLCAPS
signals O
were O
bandpass RARE
filtered RARE
in O
the O
very O
low O
- O
frequency O
range O
( O
VLF ALLCAPS
, O
0 O
. O
015 NUMERIC
- O
0 O
. O
07 O
Hz O
), O
low O
- O
frequency O
range O
( O
LF ALLCAPS
, O
0 O
. O
07 O
- O
0 O
. O
15 O
Hz O
) O
and O
high O
- O
frequency O
range O
( O
HF ALLCAPS
, O
0 O
. O
15 O
- O
0 O
. O
40 O
Hz O
) O
before O
applying O
CCF ALLCAPS
for O
the O
purpose O
of O
studying O
the O
effect O
of O
different O
bandwidths RARE
on O
the O
resulting O
mean O
CCFs RARE
. O

At O
cross O
purposes RARE
. O

For O
these O
patients O
the O
introduction O
of O
a O
separate O
category O
" O
extended O
oligoarthritis RARE
at O
onset O
" O
should O
be O
considered O
to O
establish O
comparable O
patient O
groups O
. O

The O
susceptibility O
of O
Aspergillus RARE
fumigatus RARE
to O
mulundocandin RARE
, O
an O
echinocandin RARE
- O
like O
compound O
, O
and O
other O
antifungal RARE
agents O
was O
assessed O
by O
the O
National O
Committee O
for O
Clinical O
Laboratory O
Standards RARE
( O
NCCLS ALLCAPS
) O
M38 NUMERIC
- O
P O
method O
, O
a O
2 O
, O
3 O
- O
bis RARE
( O
2 O
- O
methoxy RARE
- O
4 O
- O
nitro RARE
- O
5 O
- O
sulfophenyl RARE
)- O
5 O
-[( RARE
phenyl RARE
- O
amino O
) O
carbonyl RARE
]- RARE
2H NUMERIC
- I-GENE
tetrazolium RARE
hydroxide RARE
( O
XTT ALLCAPS
)- O
based O
colorimetric RARE
assay O
, O
and O
determination O
of O
morphologic O
alterations O
by O
microscopy O
. O

The O
most O
important O
risk O
factors O
are O
: O
1 O
) O
genetic O
; O
2 O
) O
Epstein O
- O
Barr O
virus O
( O
infectious O
mononucleosis RARE
); O
3 O
) O
congenital O
and O
acquired O
immunodeficiency O
; O
4 O
) O
occupational RARE
exposure O
( O
the O
wood RARE
industry RARE
). O

Members O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
superfamily I-GENE
of O
basic O
- O
leucine O
zipper O
factors O
bind O
to O
the O
StRE RARE
. O

DNA O
recognition O
by O
F O
factor O
TraI36 NUMERIC
: O
highly O
sequence O
- O
specific O
binding O
of O
single O
- O
stranded O
DNA O
. O

Overexpression O
of O
RORgamma RARE
has O
been O
shown O
to O
inhibit O
T O
cell O
receptor O
- O
mediated O
apoptosis O
in O
T O
cell O
hybridomas RARE
and O
to O
repress O
the O
induction O
of O
Fas I-GENE
- I-GENE
ligand O
and O
interleukin I-GENE
2 I-GENE
. O

Although O
metabolized RARE
by O
the O
cytochrome I-GENE
P I-GENE
- I-GENE
450 NUMERIC
( O
CYP ALLCAPS
) O
system O
, O
venlafaxine RARE
inhibits O
CYP ALLCAPS
2D6 NUMERIC
and O
3A4 NUMERIC
to O
a O
far O
lesser O
extent O
than O
do O
the O
SSRIs RARE
. O

SAPK I-GENE
/ I-GENE
JNK I-GENE
activation O
was O
completely O
abolished O
in O
the O
absence O
of O
MKK7 NUMERIC
, O
even O
though O
expression O
of O
MKK4 NUMERIC
was O
strongly O
upregulated RARE
in O
mkk7 NUMERIC
(-/-) RARE
mast O
cell O
lines O
, O
and O
phosphorylation O
of O
MKK4 NUMERIC
occurred O
normally O
in O
response O
to O
multiple O
stress O
stimuli O
. O

However O
these O
search O
engines RARE
respond O
with O
such O
cumbersome RARE
results O
that O
domain O
specific O
experts RARE
can O
not O
tolerate RARE
. O

The O
titer O
of O
TSH I-GENE
binding I-GENE
inhibitor I-GENE
immunoglobulin I-GENE
( O
TBII ALLCAPS
), O
which O
had O
been O
8 O
. O
6 O
% O
at O
initial O
presentation O
, O
rose O
to O
14 O
. O
9 O
% O
in O
2 O
weeks O
. O

The O
extraordinary RARE
stability O
of O
peptide O
-- O
gp96 NUMERIC
complexes O
and O
the O
plasticity RARE
of O
the O
peptide O
- O
binding O
pocket O
support O
the O
proposed O
relay RARE
of O
diverse O
peptides O
to O
MHC I-GENE
and O
/ O
or O
other O
molecules O
via O
molecular O
recognition O
. O

Elevated RARE
expression O
of O
full O
- O
length O
UhpB RARE
or O
of O
a O
soluble O
hybrid O
protein O
, O
GST I-GENE
- I-GENE
Bc RARE
, O
which O
is O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) I-GENE
fused O
to O
the O
cytoplasmic O
C O
- O
terminal O
portion O
of O
UhpB RARE
, O
results O
in O
complete O
blockage RARE
of O
uhpT LASTCAP
expression O
in O
a O
uhp RARE
(+) RARE
strain O
. O

Physical RARE
principles RARE
in O
therapeutic O
apheresis RARE
. O

Evidence O
from O
a O
Northern O
hybridization O
indicated O
that O
jadM LASTCAP
expression O
is O
correlated O
with O
jadomycin RARE
B O
synthesis O
. O

Multiple O
copies O
of O
rsmB LASTCAP
+ I-GENE
DNA O
, O
on O
the O
other O
hand O
, O
stimulate O
exoenzyme RARE
production O
by O
relieving RARE
the O
negative O
effects O
of O
a O
chromosomal O
copy O
of O
hexA LASTCAP
+. RARE

Systematic RARE
review O
of O
diagnostic O
tests O
for O
vaginal O
trichomoniasis RARE
. O

Anecdotal RARE
observations O
scattered RARE
throughout O
the O
literature O
have O
often O
provided O
clues RARE
to O
underlying O
variations O
in O
humans O
' O
ability O
to O
handle RARE
dietary O
chemicals RARE
. O

Here O
we O
show O
that O
phosphorylation O
- O
induced O
loss O
of O
the O
protein O
kinase I-GENE
activity O
of O
DNA O
- O
PK I-GENE
is O
restored O
by O
the O
addition O
of O
the O
purified O
catalytic O
subunit O
of O
either O
protein O
phosphatase I-GENE
1 I-GENE
or O
protein I-GENE
phosphatase I-GENE
2A I-GENE
( O
PP2A I-GENE
) I-GENE
and O
that O
this O
reactivation RARE
is O
blocked O
by O
the O
potent O
protein O
phosphatase I-GENE
inhibitor I-GENE
, O
microcystin RARE
. O

Herein RARE
PPARgamma I-GENE
, O
liganded RARE
by O
either O
natural O
( O
15d NUMERIC
- O
PGJ ALLCAPS
( O
2 O
) O
and O
PGD ALLCAPS
( O
2 O
)) O
or O
synthetic O
ligands O
( O
BRL49653 NUMERIC
and O
troglitazone RARE
), O
selectively O
inhibited O
expression O
of O
the O
cyclin I-GENE
D1 I-GENE
gene I-GENE
. O

An O
integrated O
RTC ALLCAPS
algorithm O
for O
the O
urban RARE
wastewater RARE
system O
is O
formulated RARE
, O
the O
parameters O
of O
which O
are O
optimized RARE
using O
various O
global O
optimization RARE
routines RARE
. O

Recently O
, O
we O
discovered O
that O
alanine O
substitutions O
of O
the O
active O
center O
cleft RARE
residues O
significantly O
impair RARE
the O
depurinating RARE
and O
ribosome O
inhibitory O
activity O
of O
PAP ALLCAPS
. O

This O
partial O
transection RARE
could O
permit O
vasopressin I-GENE
to O
be O
secreted O
in O
response O
to O
a O
larger O
rise O
in O
plasma O
sodium O
concentration O
. O

Reciprocally RARE
, O
HMGI ALLCAPS
- O
C O
expression O
also O
coordinately RARE
enhances O
PIAS3 NUMERIC
- O
mediated O
repression O
of O
STAT3 I-GENE
- I-GENE
dependent I-GENE
transactivation O
. O

The O
genomic O
structure O
of O
the O
human O
SPEC1 NUMERIC
gene I-GENE
reveals O
complex O
splicing O
and O
close O
promoter O
proximity RARE
to O
the O
AF1q NUMERIC
translocation O
gene O
. O

Here O
, O
the O
PEX5 NUMERIC
- O
TPR O
domains O
from O
human O
, O
tobacco O
, O
and O
nematode O
were O
inserted O
into O
a O
TPR O
- O
less O
yeast O
Pex5p NUMERIC
construct O
to O
generate O
Pex5p NUMERIC
chimaeras RARE
. O

This O
study O
demonstrates O
that O
inducible O
expression O
in O
response O
to O
either O
PMA O
or O
TPO ALLCAPS
is O
mediated O
through O
the O
Ets I-GENE
site I-GENE
in O
the O
proximal O
promoter O
of O
GPIX ALLCAPS
and O
is O
dependent O
upon O
the O
upstream O
activation O
of O
MAPK I-GENE
/ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
. O

Molecular O
identification O
of O
smg RARE
- O
4 O
, O
required O
for O
mRNA O
surveillance RARE
in O
C O
. O
elegans O
. O

Cytosolic RARE
acetyl I-GENE
- I-GENE
CoA I-GENE
synthetase I-GENE
( O
AceCS1 NUMERIC
) O
activates O
acetate O
to O
supply O
the O
cells O
with O
acetyl I-GENE
- I-GENE
CoA I-GENE
for O
lipid O
synthesis O
. O

There O
was O
an O
increase O
in O
protein O
binding O
onto O
this O
element O
only O
after O
peptide O
treatment O
. O

While O
these O
results O
are O
consistent O
with O
previously O
reported O
effects O
of O
the O
C O
- O
terminal O
domain O
on O
nucleotide O
binding O
, O
they O
also O
demonstrate O
that O
interactions O
with O
the O
N O
- O
terminal O
domains O
are O
necessary O
to O
inhibit O
proton O
transport O
. O

These O
findings O
suggest O
that O
an O
intracellular O
WT ALLCAPS
- O
1 O
/ O
HSAL2 NUMERIC
pathway O
may O
play O
a O
role O
in O
development O
and O
hematopoiesis RARE
. O

The O
radial RARE
forearm RARE
flap O
is O
used O
most O
commonly O
, O
however O
the O
lateral O
arm O
flap O
may O
be O
the O
flap O
of O
choice O
in O
certain O
situations O
. O

The O
procedure O
is O
less O
aggressive O
and O
painful RARE
than O
sternotomy RARE
. O

In O
addition O
, O
we O
have O
isolated O
a O
genomic O
fragment O
containing O
the O
most O
distal O
5 O
' O
sequences O
of O
the O
major O
GGT ALLCAPS
mRNA I-GENE
in O
HepG2 O
cells O
. O

Further O
, O
the O
osteo RARE
- O
retentive RARE
ability O
of O
the O
hydroxyapatite RARE
in O
the O
sockets RARE
was O
seen O
to O
be O
close O
to O
significance O
( O
after O
six O
months O
width RARE
differences O
, O
in O
the O
canine O
region O
: O
P O
= O
0 O
. O
059 NUMERIC
, O
LHS ALLCAPS
, O
and O
P O
= O
0 O
. O
065 NUMERIC
, O
RHS ALLCAPS
). O

These O
findings O
suggest O
a O
novel O
ankyrin RARE
- O
independent O
role O
for O
LAD O
- O
1 O
related O
to O
FGFR I-GENE
signaling O
. O

Managing RARE
vertigo RARE
and O
vertigo RARE
syndromes O
in O
the O
elderly O

A O
single O
base O
change O
( O
A8G NUMERIC
) O
in O
either O
sequence O
reduces O
hnRNP I-GENE
A2 I-GENE
binding I-GENE
and O
, O
in O
the O
case O
of O
A2RE NUMERIC
- O
2 O
, O
inhibits O
RNA O
transport O
. O

A O
method O
of O
three O
- O
station RARE
three O
- O
dimensional O
magnetic O
resonance O
( O
MR O
) O
angiography O
of O
the O
lower O
extremities RARE
with O
segmented RARE
volume O
acquisition O
is O
presented O
. O

Treatment O
of O
N18TG NUMERIC
- O
2 O
cells O
with O
a O
demethylating RARE
agent O
, O
5 O
- O
aza RARE
- O
deoxycytidine RARE
, O
resulted O
in O
an O
expression O
of O
mlt RARE
1 O
, O
indicating O
that O
the O
repression O
of O
mlt RARE
1 O
is O
attributable RARE
to O
methylation O
Thus O
, O
mlt RARE
1 O
is O
a O
novel O
target O
gene O
that O
is O
silenced RARE
by O
methylation O
during O
liver O
tumorigenesis O
initiated O
by O
SV40 O
T O
antigen I-GENE
. O

We O
found O
in O
the O
control O
subjects O
rCBF O
increases O
in O
regions O
associated O
with O
the O
meso RARE
- O
striatal RARE
and O
meso RARE
- O
corticolimbic RARE
circuits RARE
in O
response O
to O
both O
monetary RARE
reward RARE
and O
nonmonetary RARE
reinforcement RARE
. O

Reverse RARE
transcriptase I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
assays O
showed O
that O
PKRDeltaE7 NUMERIC
is O
expressed O
in O
a O
broad O
range O
of O
human O
tissues O
at O
variable O
levels O
. O

For O
this O
purpose O
, O
the O
immediate O
and O
the O
final O
( O
after O
swelling O
) O
fixation O
strengths O
of O
two O
variations O
of O
the O
swellable RARE
bone O
anchor O
designs RARE
( O
a O
smooth O
anchor O
and O
a O
screw RARE
anchor O
) O
were O
measured O
in O
two O
different O
foams RARE
( O
used O
to O
simulate RARE
bone O
) O
with O
different O
densities RARE
. O

CYP2C19 NUMERIC
genotype RARE
was O
determined O
by O
the O
polymerase O
chain O
reaction O
- O
restriction O
fragment O
length O
polymorphism O
method O
. O

It O
is O
useful O
as O
an O
adjunct RARE
to O
mammography RARE
in O
those O
patients O
with O
radiographically RARE
dense RARE
breasts RARE
for O
the O
characterization O
of O
palpable RARE
masses O
. O

Activation O
of O
transcription O
through O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
Jurkat O
cells O
by O
JunD RARE
and O
/ O
or O
Fra RARE
- O
2 O
was O
weak O
. O
c I-GENE
- I-GENE
Jun I-GENE
, O
JunB RARE
, O
and O
c I-GENE
- I-GENE
Fos I-GENE
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax I-GENE
. O

Thus O
, O
the O
screen O
for O
toxic O
p53 I-GENE
mutants I-GENE
in O
yeast O
can O
identify O
novel O
p53 I-GENE
variants I-GENE
that O
may O
be O
useful O
in O
dissecting RARE
p53 I-GENE
regulated I-GENE
cellular I-GENE
responses O
and O
in O
developing O
p53 I-GENE
- I-GENE
based O
cancer O
therapies RARE
. O

Local RARE
control O
rates O
were O
91 O
% O
for O
metastatic O
lung O
cancer O
, O
89 O
% O
for O
primary O
lung O
cancer O
and O
85 O
% O
for O
T1 O
, O
2N0M0 NUMERIC
cases O
. O

The O
results O
show O
that O
cognitive O
stimulation O
enhanced O
performance O
on O
the O
Boston RARE
Naming RARE
Test O
and O
a O
Word RARE
List RARE
Recognition RARE
Task RARE
; O
physical O
intervention O
, O
however O
, O
did O
not O
reach O
statistical O
significance O
. O

Gimpl RARE
, O
F O
. O

The O
actA LASTCAP
gene I-GENE
is O
present O
as O
a O
single O
copy O
in O
the O
genome O
of O
A O
. O
chrysogenum RARE
; O
and O
its O
expression O
level O
, O
opposite O
to O
pcbC LASTCAP
and O
cefEF RARE
cephalosporin RARE
biosynthetic O
genes O
, O
was O
steady O
during O
cephalosporin RARE
fermentation RARE
, O
showing O
a O
single O
1 O
. O
4 O
- O
kb O
transcript O
. O

Maternal RARE
p O
, O
p O
' O
DDE ALLCAPS
and O
beta O
- O
HCH ALLCAPS
levels O
were O
also O
associated O
with O
newborn O
levels O
, O
but O
levels O
of O
PCBs RARE
were O
not O
. O

The O
patients O
and O
their O
families O
were O
closely O
questioned RARE
, O
and O
full O
clinical O
examination O
included O
a O
test O
for O
orthostasia RARE
. O

The O
expression O
of O
alpha I-GENE
- I-GENE
amylase I-GENE
can O
be O
transactivated O
by O
the O
transcription O
factor O
GAMyb RARE
, O
which O
is O
itself O
induced O
by O
GA ALLCAPS
. O

Cardiac RARE
output O
at O
anaerobic O
threshold O
( O
COAT ALLCAPS
) O
< O
or O
= O
7 O
. O
3 O
L O
/ O
min O
was O
the O
best O
cutoff O
value O
for O
identifying O
multivessel RARE
coronary O
artery O
disease O
( O
relative O
risk O
, O
3 O
. O
1 O
). O

Tolerance RARE
to O
ADAL ALLCAPS
- O
2 O
was O
similar O
to O
that O
of O
Vicryl RARE
suture RARE
and O
tolerance O
to O
ADAL ALLCAPS
- O
2 O
was O
superior O
to O
that O
to O
Tisuacryl RARE
. O

In O
the O
base O
- O
case O
analysis O
, O
total O
direct O
costs O
per O
patient O
were O
$ RARE
728 NUMERIC
for O
zoledronic RARE
acid O
and O
$ RARE
776 NUMERIC
for O
pamidronate RARE
. O

METHODS O
: O
We O
retrospectively RARE
selected O
13 O
TFCD ALLCAPS
patients O
who O
underwent O
surgery O
for O
intractable RARE
epilepsy O
with O
the O
aim O
of O
removing O
the O
magnetic O
resonance O
( O
MR O
)- O
detectable O
lesion O
and O
/ O
or O
the O
epileptogenic RARE
zone O
defined O
by O
stereoelectroencephalographic RARE
recordings O
. O

To O
gain O
an O
understanding O
of O
the O
mGSTM2 NUMERIC
regulation O
, O
we O
have O
also O
cloned O
and O
analyzed O
its O
promoter O
region O
. O

Cyclins RARE
are O
one O
of O
the O
pivotal O
determinants O
regulating O
cell O
cycle O
progression O
. O

Architecture RARE
and O
anatomy RARE
of O
the O
genomic O
locus O
encoding O
the O
human O
leukemia O
- O
associated O
transcription O
factor O
RUNX1 NUMERIC
/ O
AML1 NUMERIC
. O

Three O
of O
the O
proteins O
involved O
in O
checkpoint O
signaling O
, O
Rad1 NUMERIC
, O
Hus1 NUMERIC
, O
and O
Rad9 NUMERIC
, O
have O
been O
shown O
to O
interact O
by O
immunoprecipitation O
and O
yeast O
two O
- O
hybrid O
studies O
. O

Together O
these O
data O
imply O
that O
the O
HFV ALLCAPS
R I-GENE
region I-GENE
acts O
in O
the O
nucleus O
to O
modify O
the O
cytoplasmic O
fate O
of O
target O
HFV ALLCAPS
mRNA I-GENE
. O

However O
, O
patients O
with O
isolated O
office RARE
hypertension O
had O
fewer O
previous O
cardiovascular O
complications O
. O

Through RARE
deletion O
mutagenesis O
, O
we O
identify O
amino O
acids O
2003 NUMERIC
to O
2212 NUMERIC
of O
CBP I-GENE
, O
which O
we O
call RARE
carboxy O
- O
terminal O
region O
2 O
( O
CR2 NUMERIC
), O
as O
the O
minimal O
region O
for O
Tax I-GENE
interaction O
. O

Fetal RARE
lung O
volume O
: O
estimation O
at O
MR O
imaging O
- O
initial O
results O
. O

Plane RARE
wave O
geometry RARE
is O
impractical RARE
for O
clinical O
use O
but O
the O
results O
of O
this O
work O
encouraged RARE
us O
to O
further O
develop O
the O
P3 O
approximation RARE
for O
a O
spherical RARE
geometry RARE
, O
described O
in O
this O
paper O
. O

For O
the O
sample O
of O
systematic O
reviews RARE
drawn RARE
from O
ACP ALLCAPS
Journal RARE
Club RARE
( O
n O
= O
103 NUMERIC
), O
the O
PubMed RARE
strategy O
achieved O
a O
sensitivity O
of O
97 O
% O
( O
CI O
, O
91 O
% O
to O
99 O
%). O

In O
addition O
to O
that O
, O
she RARE
received O
hepatic O
intra O
- O
arterial O
infusion O
of O
levoforinate RARE
( O
l O
- O
LV O
) O
250 O
mg O
and O
5 O
- O
fluorouracil O
( O
5 O
- O
FU O
) O
500 O
mg O
for O
combined O
multiple O
hepatic O
metastases O
starting O
on O
postoperative O
day O
14 O
, O
and O
these O
medications RARE
were O
administered O
over O
48 O
hours O
once O
weekly O
by O
infuser RARE
pump O
. O

Because O
of O
differences O
in O
patient O
characteristics O
, O
control O
measurements O
were O
obtained O
from O
normal O
muscle O
in O
all O
patients O
. O

Two O
families O
with O
concordant RARE
inheritance RARE
of O
DNAH9 NUMERIC
alleles I-GENE
in O
affected O
individuals O
were O
observed O
. O

NIRS ALLCAPS
was O
used O
for O
the O
quantitative O
measurement O
of O
muscle O
O O
( O
2 O
) O
consumption O
( O
mV LASTCAP
. O
O O
( O
2 O
)) O
and O
forearm RARE
blood O
flow O
( O
FBF ALLCAPS
) O
in O
78 O
healthy O
subjects O
. O

Many O
factors O
do O
influence O
the O
educational RARE
outcome O
in O
students O
and O
large O
statistical O
power O
( O
such O
as O
meta RARE
analysis O
) O
should O
be O
helpful O
to O
eliminate RARE
many O
sources O
of O
error O
. O

B O
- O
myb I-GENE
is O
essential O
for O
G1 O
/ O
S O
transition O
and O
has O
been O
shown O
to O
be O
phosphorylated O
by O
the O
cyclin I-GENE
A2 I-GENE
/ I-GENE
cdk2 I-GENE
complex I-GENE
. O

Like O
the O
consensus O
mammalian O
LHbeta RARE
gene I-GENE
, O
the O
5 O
'- O
flanking O
region O
of O
the O
gpLH RARE
/ O
CGbeta RARE
gene I-GENE
contains O
a O
single O
TATA O
sequence O
37 O
bp O
upstream O
of O
the O
translation O
start O
codon O
. O

HTLV O
- O
1 O
decreases O
Th2 NUMERIC
type O
of O
immune O
response O
in O
patients O
with O
strongyloidiasis RARE
. O

Indeed O
, O
mutation O
of O
two O
of O
these O
motifs O
, O
known O
to O
be O
important O
to O
regulation O
of O
sid1 NUMERIC
, O
altered O
the O
differential O
regulation O
of O
sid2 NUMERIC
by O
iron O
. O

Nutritional RARE
status O
in O
adults O
on O
an O
alternative O
or O
traditional RARE
diet O
] O
BACKGROUND O
: O
Plant RARE
food O
lacks O
vitamin O
B12 NUMERIC
, O
vitamin O
D O
and O
higher O
n O
- O
3 O
polyunsaturated RARE
fatty O
acids O
. O

On O
the O
other O
hand O
, O
forced RARE
overexpression O
of O
the O
wild O
type O
, O
but O
not O
the O
kinase I-GENE
- I-GENE
inactivated O
mutant I-GENE
of O
nm23H1 NUMERIC
, O
converted O
the O
GDP O
- O
bound O
forms O
of O
Rac1 I-GENE
, O
Cdc42 I-GENE
, O
and O
RhoA I-GENE
to O
their O
GTP O
- O
bound O
forms O
in O
vitro O
by O
its O
nucleoside RARE
diphosphate RARE
kinase I-GENE
activity O
, O
but O
nm23H1 NUMERIC
alone O
apparently O
did O
not O
produce O
the O
GTP O
- O
bound O
form O
of O
these O
GTPases I-GENE
in O
vivo O
. O

Novel RARE
intronic O
promoter O
in O
the O
rat O
ER O
alpha I-GENE
gene I-GENE
responsible O
for O
the O
transient O
transcription O
of O
a O
variant O
receptor O
. O

RESULTS O
: O
Coronary O
mortality O
during O
the O
median O
follow O
- O
up O
time O
of O
17 O
months O
was O
6 O
- O
fold O
higher O
in O
the O
highest O
tertile RARE
for O
CRP I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
and O
3 O
. O
5 O
- O
fold O
higher O
in O
the O
highest O
tertile RARE
for O
fibrinogen I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
than O
in O
the O
respective O
combined O
lower O
tertiles RARE
. O

HIV O
- O
1 O
and O
hepatitis O
B O
virus O
infections O
in O
adolescents RARE
lodged RARE
in O
security RARE
institutes RARE
of O
Buenos RARE
Aires RARE
. O

However O
, O
the O
promoter O
region O
contains O
several O
potential O
cis O
- O
regulatory O
elements O
such O
as O
Sp1 I-GENE
, O
early O
growth O
response O
- O
1 O
, O
activator O
protein O
- O
2 O
, O
MyoD I-GENE
, O
p300 I-GENE
, O
nuclear O
factor O
- O
kappaB I-GENE
, O
myeloid O
zinc O
finger O
protein O
- O
1 O
, O
caudal RARE
- O
related O
homeobox I-GENE
( O
Cdx RARE
) O
gene O
A O
, O
and O
Cdx RARE
protein O
- O
2 O
binding O
sites O
. O

RPM ALLCAPS
/ O
RGL3 NUMERIC
resembled RARE
AF O
- O
6 O
and O
Nore1 NUMERIC
in O
interacting O
strongly O
with O
constitutively O
active O
M O
- O
Ras I-GENE
and O
p21 I-GENE
Ras I-GENE
. O

METHODS O
: O
93 O
female O
and O
43 O
male O
patients O
undergoing O
thyroid O
surgery O
were O
stratified RARE
according O
to O
gender O
and O
then O
randomised O
to O
receive O
double O
- O
blind O
one O
of O
four O
antiemetic RARE
regimes RARE
: O
50 O
mg O
dolasetron RARE
given O
orally O
45 O
minutes O
prior O
to O
induction O
of O
anaesthesia O
( O
group O
I O
), O
12 O
. O
5 O
mg O
dolasetron RARE
given O
intravenously O
during O
induction O
of O
anaesthesia O
( O
group O
II O
), O
1 O
. O
25 O
mg O
DHB ALLCAPS
given O
intravenously O
during O
induction O
of O
anaesthesia O
( O
group O
III O
) O
or O
placebo O
( O
group O
IV O
). O

Transcriptional O
regulation O
of O
the O
estrogen O
- O
inducible O
pS2 NUMERIC
breast O
cancer O
marker O
gene O
by O
the O
ERR ALLCAPS
family I-GENE
of O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
. O

